Positive Outcomes Prompt ECMO Trial’s Early End

One life saved for every six treated.

BY BETSY BATES
Elsevier Global Medical News

HONOLULU — One additional patient survived for every six patients treated with extracorporeal membrane oxygenation in a large randomized study comparing the modality to conventional ventilatory support in patients with severe but potentially reversible adult respiratory failure.

Among 90 patients assigned to receive extracorporeal membrane oxygenation (ECMO), 57 (63%) were alive without severe disability 6 months following conventional ventilatory support compared with 41 (47%) who received conventional mechanical ventilation in specialized intensive care units in the United Kingdom.

The results of the CESAR trial (Conventional Ventilatory Support Versus Extracorporeal Membrane Oxygenation for Severe Adult Respiratory Failure) were particularly striking because British researchers used an intent-to-treat analysis that included 22 patients who ultimately failed to receive ECMO, because they either began improving on their own or died before treatment could be initiated. That leaves the possibility that the magnitude of ECMO may be even greater among well-selected patients.

So profound was the impact of ECMO, in fact, that the data monitoring committee stopped the trial early, when 90 patients out of the planned enrollment of 128 had been randomized to each group.

The CESAR trial was conducted throughout the United Kingdom, and more than half of the intensive care units in the country participated by referring potential candidates for randomization. All ECMO was performed at Glenfield Hospital in Leicester, England, and the modality was available at no other center in the country during the study period.

Patients in the two groups

See Early End • page 2

Survival Up for Downstaged Lung Cancer

BY DAMIAN MCNAMARA
Elsevier Global Medical News

FORT LAUDERDALE, Fla. — Stage IIIA non-small cell lung cancer patients who achieve stage 0 or I disease following chemoradiotherapy induction have improved long-term surgery survival rates, but these are significantly lower than survival rates in stage I patients who have surgery only, according to a retrospective study.

Previous research demonstrated a survival benefit to downsizing stage II non-small cell lung cancer (NSCLC). For example, of 53 patients treated with chemoradiotherapy induction, 22 achieved a major pathologic response and were reclassified as stage 0, I, or II in one report (J. Thorac. Cardiovasc. Surg. 2004;127:108-13). Compared with a 24% survival rate among nonresponders, the downsized group had a 48% survival rate. The 3-year actuarial survival was 31%.

In another study, researchers found a 67% tumor downstaging and an “encouraging” 77% 5-year survival among 42 patients with advanced NSCLC who were also treated with chemoradiotherapy (J. Clin. Oncol. 1997;15:712-22).

Again, a significantly better survival rate was observed among downstaged participants. “Our study confirmed this,” Dr. Stefano Mancagorta said at the annual meeting of the Society of Thoracic Surgeons.

“But going further into this problem, do cases with stages 0-1 after induction therapy have the same prognosis as surgery?”

See Lung Cancer • page 10

Pulmonary Medicine
Hot Tub Trouble
Non tuberculous mycobacteria lurk behind difficult-to-diagnose hot tub lung. • 3

Critical Care Medicine
Speed Rounds
Critically ill patients seen later in rounds were less likely to receive a physical examination. • B

News From the College
Awards Season
The deadline to apply for The CHEST Foundation 2008 Awards is April 30. • 15

Palliative Care
Final Conflict
How to approach family conflicts over a patient’s end of life care. • 21
were well balanced by age, hours of high pressure and/or high FiO2 ventilation, underlying diagnosis (pneumonia, trauma, obstructive, or other acute respiratory distress syndrome), number of organs failed, and type of referral hospital.

Dr. Giles Peak, who presented preliminary study findings at the Society of Critical Care Medicine annual congress, said the “real-world” study design reflects current practice in the United Kingdom.

Currently, ECMO is widely used in neonatal intensive care units to temporarily provide gas exchange to provide rest for the lungs during respiratory failure. While ECMO is also in widespread use for children and newborns in the United States and Canada, only a handful of U.S. Canadian hospitals practice adult ECMO, said Dr. Peak.

In both adults and infants, high airway pressures and oxygen concentrations associated with conventional mechanical ventilation are known to traumatize the lungs, yet previous studies of ECMO in adults have been inconsistent and inconclusive.

The CESAR trial was designed to determine on a large scale, in a randomized fashion, whether ECMO offers lung protective advantages to adults with a variety of conditions leading to respiratory distress. Eligible patients included individuals aged 18-65 years with severe, potentially reversible adult respiratory failure, defined as having a Murray score of 3 or greater, hypocapnia with a pH of less than 7.2. If they met these criteria, they were randomized to be transferred to Glenfield Hospital, Leicester, where all ECMO was performed, or to receive conventional care at a tertiary center.

Patients were excluded if they had experienced prolonged (more than 7 days) of high peak pressure or high FiO2 ventilation (more than 0.8), or if they had a contraindication to heparin.

Most enrolled patients suffered from pneumonia or nonobstructive acute respiratory distress syndrome (ARDS), followed by trauma. A significant number had failure of more than one organ system, demonstrating ECMO’s usefulness in multorgan failure, said Dr. Peak.

The median time on ventilation prior to randomization was about 35 hours in both treatment groups. Among patients randomized to receive venovenous ECMO the mean time to beginning ECMO was 6.1 hours. The mean duration of ECMO was 9 days. The majority of patients had hypoxia, with a small number of patients experiencing uncompensated hypercapnia. The mean APACHE score assessing severity of illness was 20.

More patients died in the conventional treatment arm versus the ECMO group, 45 versus 33, but the difference was not statistically significant. Among patients who died, those receiving conventional care died more quickly.

Overall, ECMO reduced death or significant morbidity in 6 months regardless of patients’ stratification criteria, including age, number of organs involved, or severity of illness.

“I expect conventional practice to slowly embrace the use of ECMO for adults with severe but potentially reversible respiratory failure,” Dr. Peak predicted.

ECMO Improved Survival in Adults

Approach Boosts Quit Rate

Lung Age Calculations

For men:
Lung age = (2.87 × height [in inches]) − (31.25 × observed FEV1 [in liters]) − 39.75

For women:
Lung age = (3.56 × height [in inches]) − (40 × observed FEV1 [in liters]) − 77.28

ECMO Improved Survival in Adults

Early End • from page 1

CheST Physician

CHEST Physician, the newspaper of the American College of Chest Physicians, provides cutting-edge reports from clinical meetings, FDA coverage, clinical trial results, expert commentary, and reporting on the business and politics of chest medicine. Each issue also provides material exclusive to the members of the American College of Chest Physicians.

CHEST Physician is available on the Web at www.chestnet.org/about/publications.
Hot Tub Lung Eludes Diagnosis, Optimal Treatment

By Bruce Jancin
Elsevier Global Medical News

Keystone, Colo. — Hot tub lung is a common, frequently misdiagnosed, and particularly fascinating form of nontuberculous mycobacterial pulmonary disease, according to a researcher from the National Jewish Medical and Research Center, Denver.

Hot tub lung is believed to be a hypersensitivity pneumonitis caused by exposure to aerosolized Mycobacterium avium complex (MAC) and other nontuberculous mycobacteria (NTM) predisposed to grow in indoor hot tubs, enclosed swimming pools, spas, and therapy pools.

“The thought is the lung is overresponding to an antigen. What we don’t know is whether it’s simply an immune response to an antigen or a true infection with an NTM organism,” Dr. Gwen A. Huitt said at a meeting on allergy and respiratory diseases sponsored by the National Jewish Medical and Research Center.

And that unresolved question bears on the issue of optimal treatment. “We still don’t have a conclusion as to what the right treatment is: strict exposure avoidance and prednisone, or antibiotics as well. I think the jury is definitely still out,” said Dr. Huitt, director of the adult infectious disease care unit and chairman of the infection control committee at the center.

Indeed, Dr. Huitt noted that in a recent series of 27 patients with hot tub lung reported by her colleagues in the occupational medicine group at National Jewish, the disease resolved or improved with treatment in all cases. However, one-third of patients were left with a mild fixed, permanent residual impairment in lung function as evidenced by a diffusing capacity of the lung for carbon monoxide less than 80% of normal. So hot tub lung is not necessarily a benign process.

All patients were treated with exposure avoidance, 13 got oral prednisone alone tapered over 4-8 weeks, and 12 got prednisone plus 3-6 months of triple-agent anti-mycobacterial therapy. There was no significant difference in the residual impairment rate between patients treated with or without the anti-mycobacterial medications (J. Occup. Environ. Hyg. 2007;4:831-40).

Her tentative conclusion? “Prednisone may be enough as long as you’re avoiding the exposure,” she said.

Patients with hot tub lung typically are previously healthy and younger than those with other NTM-associated pulmonary disease.

Recreational tub and pool users aren’t the only at-risk population. The disease also occurs in pool maintenance workers, lifeguards, and water therapists, raising occupational health issues.

The main presenting symptoms of hot tub lung are subacute-onset shortness of breath, cough, and fatigue. “Many of these patients feel like they have a slow-onset flu. They’re achy, tired, have a prominent cough or arthralgias,” according to Dr. Huitt.

Chest x-rays will show diffuse infiltrates with prominent nodularity in all lung fields. CT scans often show intense inflammation with centrilobular nodules, ground-glass opacities in a mosaic pattern, and air trapping.

The diagnosis of hot tub lung is based upon a history of exposure, compatible radiographic studies, and positive cultures for NTM obtained from the hot tub water as well as from sputum, bronchoalveolar lavage, or lung biopsy.

Pulmonologists at National Jewish have found that lidocaine is bactericidal to NTM; they’ve learned to rely instead on conscious sedation in order to avoid false-negative cultures when performing bronchoscopy in patients with suspected NTM.

Interestingly, the referral diagnosis was hypersensitivity pneumonitis in only 8 of the 27 patients in the recent National Jewish series. One-quarter of patients had a working diagnosis of sarcoidosis, probably because lung biopsies obtained at other centers showed granulomas. But the granulomas characteristic of hot tub lung are discrete, nonnecrotizing, and distributed in a bronchocentric and centrilobular fashion, in contrast to sarcoidosis.

The rest of the patients were misdiagnosed elsewhere as having asthma, pneumo-nia, emphysema, tuberculosis, bronchiolitis obliterans, or interstitial lung disease.

Dr. Huitt recalled a recent consult she received from public health workers regarding a family of five who had been diagnosed with TB and quarantined while undergoing anti-TB therapy.

“It was a well-to-do white family living in an affluent community, and they had no history of travel to an endemic area. Dr. Huitt grew suspicious. Do they have an indoor hot tub? she asked. Sure enough, they did. And depressed by the quarantine and TB drug side effects, they were spending a lot more time in it than usual, and—strangely enough—feeling worse and worse. They hadn’t changed the water in months and months—it’s quite expensive—although they regularly dumped in disinfectant chemicals. A thorough work-up revealed all five had hot tub lung rather than TB.

Dr. Huitt’s preferred method of NTM exposure avoidance involves ripping out the hot tub. She stressed that while hot tub manufacturers tout their disinfectant systems, which often rely on UV light, bromine, chlorine, or ozone, none of them kills mycobacteria.

“The word needs to get out: ‘The only thing that really works is changing the water,’ she said.

‘After a nuclear bomb, there will still be cockroaches and mycobacteria.’

Dr. Philip Marcus, FCCP, comments: “Hot tub lung” has been recognized for several years. Clearly, this shows the importance of taking a complete history in terms of extraneous, environmental factors. As this article emphasizes, we need to focus on in-home factors as well. In addition, paying attention to the heating system, humidification, age of the home, and many other factors will help establish a diagnosis more quickly. Mycobacterial infection is something that can be treated when recognized. This study also points out the importance of common sense issues such as changing the water.

FDA Issues Warning About Prescription Cough Product

By Elizabeth Mechcatie
Elsevier Global Medical News

Deaths and life-threatening side effects associated with the misuse of a long-acting, prescription cough medicine that contains hydrocodone have prompted the Food and Drug Administration to issue a public health advisory about the dangers of the product when not used properly.

The product is marketed as Tussionex Pennkinetic Extended-Release Suspension, a combination of the narcotic hydrocodone and the antihistamine chlorpheniramine, which is approved for adults and for children age 6 and under.

It should not be given more frequently than every 12 hours and is contraindicated in children under age 6, according to the FDA advisory, which was issued on March 11.

The FDA has received “numerous” reports of deaths and other adverse events in adults and children “associated with the misuse and inappropriate use of this potent cough medicine,” said the statement.

The reports indicate that physicians and other health professionals have prescribed Tussionex for children who are under age 6, or more frequently than the labeled dosage interval of every 12 hours. In addition, the reports indicate that patients have taken the incorrect dose because they have misinterpreted the dosing directions on the medication label, which calls for using multiple inappropriate devices to measure the suspension. (There are other hydrocodone-containing cough products that can be administered at an interval of every 4-6 hours.)

“There is a real and serious risk for overdosing if this medication is not used according to the labeling,” said Dr. Curtis Rosebraugh, acting director of the FDA’s Office of Drug Evaluation II, in the statement. Overdoses in children who are older than 6 years, adolescents, and adults have also resulted in life-threatening and fatal cases of respiratory depression.

Tussionex is manufactured by UCB Inc., which has agreed to update the labeling to include information that the product should not be used in children under age 6, and that it should be dosed accurately.

In addition to the warning not to use the product in children younger than age 6 years, the advisory recommends that health care professionals consult the prescribing information to determine the correct dose and dosing frequency of Tussionex. The FDA’s other recommendations for using the product safely include the following:

• Health care professionals should not prescribe Tussionex to be taken more frequently than every 12 hours.

• Health care professionals and patients who use the product should be aware of the signs of hydrocodone overdose.

Prescribers should clearly state the prescribed volume in milliliters. Pharmacists should clearly state directions in milliliters on the prescription container, and provide a measuring device that delivers the volume in milliliters. (The FDA has received some reports indicating that the volume prescribed by the physician was incorrectly converted to another volume on the prescription label, such as 2 ml to 2 teaspoons.)

• Patients should be counseled about the amount of Tussionex that should be given and at what frequency.

More information is available at www.fda.gov/over/drgu/information/hydrocodone. Adverse reactions to this product should be reported to the FDA’s MedWatch program at 800-332-1088 or www.fda.gov/medwatch.
Mepolizumab, a fully humanized monoclonal interleukin-5 antibody, significantly reduced the need for prednisone in patients with hypereosinophilic syndrome, according to an article published in the New England Journal of Medicine.

Hypereosinophilic syndrome (HES) is typically treated with prednisone or equivalent corticosteroids, and the 85 patients in the study were all stabilized on doses of 20-60 mg of prednisone daily before being randomized to mepolizumab or placebo.

By the end of the 36-week study, 84% of the patients taking mepolizumab were able to reduce their daily dose of prednisone to 10 mg or less for at least 8 weeks. In contrast, only 41% of the patients receiving placebo were able to decrease their daily dose of prednisone to 10 mg or less for 8 weeks (N. Engl. J. Med. 2008;358:1215-28).

On average, patients receiving mepolizumab were able to reduce their prednisone dose from 22 mg to 6.2 mg, while patients receiving placebo reduced their daily prednisone dose from 30.6 mg to 21.8 mg, a statistically significant difference.

The double-blind study, led by Dr. Marc E. Rothenberg of the University of Cincinnati and colleagues, involved 85 patients with HES who were seen at 1 of 26 sites in the United States, Canada, Belgium, France, Germany, Italy, Switzerland, and Australia. All patients had a blood eosinophil count greater than 1,500/μl for at least 6 months, along with eosinophilia-related organ involvement and no identifiable secondary cause for eosinophilia. Patients who tested positive for the FIP1L1/PDGFRA fusion gene, which can cause HES, were excluded from the study.

Mepolizumab also proved superior to placebo on several secondary end points as well. About 95% of patients receiving mepolizumab had an eosinophil count of less than 600/μl for 8 weeks or more, compared with 45% of the patients receiving placebo. Serum levels of the neurotoxins derived from eosinophils were significantly lower in the mepolizumab group than in the placebo group at all time points tested: 12, 24, and 36 weeks.

Seven patients receiving mepolizumab and five patients receiving placebo experienced serious adverse events, but none was judged to be related to the drug. Other adverse events occurred at similar rates in the two groups, with fatigue, pruritus, headache, and arthralgia the most common.

One patient in the mepolizumab group and four in the placebo group withdrew from the study because of adverse events.

Regulatory authorities in the United States and the European Union have granted mepolizumab orphan drug status.

According to some estimates, between 2,000 and 5,000 people in the United States suffer from HES. Manufactured by GlaxoSmithKline, mepolizumab (trade name Bosfasta) is still considered an investigational drug.

The study was supported in part by GlaxoSmithKline, several of the paper’s coauthors are employees of GlaxoSmithKline, and Dr. Rothenberg and several other coauthors reported receiving consulting fees from that company.

Despite the encouraging results, several important questions remain unanswered, Dr. Michael E. Wescler (Brigham and Women’s Hospital, Boston) wrote in a companion editorial. For example, it’s unknown how long the effects of mepolizumab will last, whether rebound eosinophilia will occur when treatment is stopped, or what the ideal dose to achieve a sustained response will prove to be (N. Engl. J. Med. 2008;358:1293-4).

Mepolizumab is an anti-interleukin-5 antibody, and Dr. Wescler wondered whether this or other similar drugs would prove effective in other disorders such as eosinophilic esophagitis, eosinophilic pneumonia, asthma with eosinophil-predominant phenotypes, or Churg-Strauss syndrome.

Anti-interleukin 5 treatment certainly brings new hope to patients with the hypereosinophilic syndrome whose disease is currently refractory to conventional therapies or who have side effects from them,” Dr. Wescler wrote.

It is important to recognize that this therapy’s greatest contribution may be to teach us about the biologic characteristics of the eosinophils,” he added.

Dr. Wescler reported receiving research support, consulting fees, and lecture fees from GlaxoSmithKline and several other pharmaceutical companies.

FD A Investigating Reports of Suicidality in Singular Users

The Food and Drug Administration issued an “early communication” to health care professionals on March 27 that it is reviewing postmarketing reports it has received of behavior/ mood changes, suicidality, and suicide in patients who have taken the asthma and allergy medication montelukast (Singular), although the agency has declined to say how many reports it has received.

Dr. George Philip, senior director of clinical research at Merck & Co., which makes Singular, also said the company would not reveal any more specific data at this time. “We think that sharing those numbers is ultimately not very useful,” said Dr. Philip in an interview.

An FDA spokeswoman said the agency had received reports of three or four suicides in patients taking Singular. But no causal relationship can be established, noted Merck. Merck agreed that reports did not equal a relationship. “The fact that an adverse event has been reported to Merck and to regulatory agencies does not reflect a conclusion that the postmarketing event is caused by Singular,” said the company in a statement.

The company picked up a signal of potential psychiatric adverse events through anecdotal reports submitted to Merck over the last year or so as part of routine postmarketing surveillance, said Dr. Philip. Merck updated Singular’s label in October 2007 to reflect a potential association with suicidality.

In the past year, Merck has also added information that the leukotriene receptor antagonist has been associated with tremor, depression, and anxiety.FDA and Merck officials met this past February to discuss how best to communicate the label changes to physicians, patients, and others, said Dr. Philip. Merck already has been—and will continue to—communicate directly with physicians through face-to-face meetings.

An initial review of clinical trial data found no evidence of an association with mood changes, according to Dr. Philip.

“In a cumulative analysis recently provided to the FDA of Merck’s randomized, double blind, placebo-controlled clinical trials, which included over 11,000 adults and children in over 40 studies who were treated with Singular, there were no reports of suicidal thoughts or actions or no completed suicides in the patients who received Singular,” the company’s statement said.

The FDA has asked Merck to review all its clinical data for evidence of suicidality or suicide. And the agency is also reviewing the postmarketing reports it has received on behavior and mood changes, suicidality, and suicide. The FDA said its investigation will take 9 months to complete.

In the meantime, patients should not stop taking Singular, said the FDA and Dr. Philip. The agency did urge physicians to monitor patients for signs of suicidality and other psychiatric events.

The FDA is also reviewing postmarketing reports it has received of behavior/mood changes, suicidality, and suicide in patients who took other leukotriene-modifying therapies, including zafirlukast (Accolate) and zileuton (Zyflo and Zyflo CR). The agency will then assess whether further investigation is warranted.

Oral Drug for CF Shows Promise in Early Trials

A drug designed to fix a crucial defective protein in cystic fibrosis improved patients’ lung function and sweat chloride levels, according to early results from a small randomized study.

The investigational oral drug, VX-770, is still in phase II trials. But the preliminary findings among 20 patients—particularly the impact on sweat chloride levels—are generating cautious optimism.

“These early results are an extraordinary endorsement of our hypothesis—that small molecules can correct the basic defect and affect the clinical indicators of cystic fibrosis,” Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation, said in a statement.

VX-770 targets defective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) proteins in sweat duct epithelial cells. Dysfunctional CFTR proteins are believed to cause the fluid and salt imbalance that characterizes CF patients’ airways.

The first part of the phase Ia trial included 20 patients who carry the G551D mutation in the CFTR gene. About 4% of CF patients in the United States carry the G551D mutation. Patients participated in two 14-day treatment periods. In addition to standard CF therapies, patients received either placebo or one of three VX-770 dosage levels during each 14-day period.

At the end of 14 days, patients who received the highest dose of VX-770 (150 mg twice daily) experienced an average 10.1% increase in forced expiratory volume in 1 second (FEV1), compared with an average FEV1 decrease of less than 1% in placebo patients.

Patients on high-dose VX-770, sweat chloride levels fell from an average 95.9 mmol/L at baseline to 53.2 mmol/L after 14 days of treatment. Patients on placebo had no significant change in sweat chloride levels. Sweat chloride levels for CF patients typically are greater than 60 mmol/L, compared with normal values of less than 40 mmol/L in people without CF.

The adverse event profile was similar between VX-770 and placebo. One patient experienced two serious adverse events, which researchers deemed not related to VX-770.

The second stage of the drug’s phase IIa trial is slated to begin later this year, and will enroll 16 patients for 28 days of randomized, placebo-controlled treatment. A phase IIB trial may begin in 2009, according to the Cystic Fibrosis Foundation.

Vertex Pharmaceutical Inc. is developing VX-770 and a compound, VX-809, with funding support from the Cystic Fibrosis Foundation.

PULMONARY MEDICINE  CHEST Physician • APRIL 2008
SAVE THE DATE

Inaugural Meeting of the US Critical Illness and Injury Trials Group held in conjunction with the 6th Symposium on the Functional Genomics of Critical Illness and Injury

November 17-19, 2008
National Institutes of Health
Bethesda, Maryland, USA

Steering Committee
Anthony F. Sfondilis, MD
Critical Care Medicine Department
NIH Clinical Center, DHHS
Scott Samore, PhD
National Institute of General Medical Sciences, NIH, DHHS
Carol Nicholas, MD
National Institute of Child Health and Human Development, NIH, DHHS
Peter Marsden, PhD
Center for Information Technology
NIH, DHHS
Ramona Hicks, PhD
National Institute of Neurological Disorders and Stroke, NIH, DHHS
Andrea Harabin, PhD
National Heart Lung and Blood Institute, NIH, DHHS
Robert L. Damrauer, MD
Critical Care Medicine Department
NIH Clinical Center, DHHS
J. Peran Cobb, M.D.
Washington University in St. Louis

Organizing Committee
Derek Angus, MD, MPH
University of Pittsburgh
Eileen Buiger, MD
University of Washington
Charles Carms, MD
University of North Carolina at Chapel Hill
Nina Gentile, MD
Temple University
David Hoyt, MD
University of California at Irvine
Poly Parsons, MD
University of Vermont College of Medicine
Debra Schwinn, MD
University of Washington
Jeffrey Upperman, MD
University of Southern California
Joanne Wuorinen, MD
University of California at San Francisco
Hector Wong, MD
Cincinnati Children’s Hospital Medical Center

Scientific leaders within the United States critical illness and injury community met at the 5th NIH Functional Genomics of Critical Illness and Injury Symposium, November 14-15, 2007 to discuss a strategic plan for critical illness and injury clinical research in the United States. Representative views were gathered from a broad spectrum of stakeholders, including professional organizations, academic centers, federal agencies, and industry. Group discussion affirmed that success could only come from cooperative and strategic actions that favor collaboration, standardization of protocols, and strong leadership.

The United States Critical Illness and Injury Trials Group (USCIITG) is funded by the National Institute of General Medical Sciences to create a clinical research framework that will reduce the barriers to investigation using the same investigator-initiated, evidence-driven, inclusive approach that has proven successful elsewhere. The USCIITG will not fund clinical trials, but rather will promote the development of evidence-based clinical protocols and the subsequent preparation of applications for funding to test specific hypotheses. Investigators that span the gamut of critical illness and injury specialties will be involved in this collaborative effort.

The specific aims of the USCIITG include the following:

- Establish an inclusive, nationwide network of experts to review published data, establish national priorities, vet hypotheses, write clinical protocols, and generate pilot data;
- Promote interactions and synergy across established programs — both academic and non-academic — to improve the robustness (power) of clinical trials and test hypotheses in U.S. populations across the patient age continuum;
- Provide a venue to discuss education and training in the science of clinical trial design including, conduct, analysis, and reporting for critically ill or injured patients; and
- Insure patient protection and privacy by addressing the ethical, legal, and social implications of research in the specialized circumstance of critical illness or injury.

It is expected that the USCIITG will not act in isolation, but will be part of a larger effort to bridge critical care trials groups worldwide. Its success will be based on collaborative leadership, non-hierarchical team culture, and open dialog among participants that will facilitate communication streams and help link new scientific knowledge with practice.

For more information: www.usciitg.wustl.edu
Budget Shortages Weaken Worldwide Fight Against TB

By Jonathan Gardner
Elsevier Global Medical News

The pace of progress has slowed in the global battle against the tuberculosis epidemic, according to a World Health Organization report published March 17. Between 2001 and 2005, the average rate at which new TB cases were detected was increasing by 6% per year; between 2005 and 2006 that rate of increase was cut in half, to 3%, the WHO’s 12th annual report on global tuberculosis control said.

The reason for the slowdown is that in some countries, programs that were having great success against TB have been unable to continue at the 2006 pace. Budget shortages are having a heavy impact on efforts: The 90 countries (with 91% of global cases) that provide data reported funding gaps totaling $385 million in 2008.

Only 5 of the 22 high-burden countries reported no funding gap, the report said.

The budget needed to meet the international goal set by the United Nations for 2008 is currently facing a shortfall of about $1 billion. The WHO reported that in 2006 there were 9.2 million cases of tuberculosis (139 per 100,000 people), up from 9.1 million cases in 2005. In 1990 there was an incidence of 6.6 million cases (124 per 100,000).

The UN used 1990 as a baseline for measuring progress in TB control. The rate of decrease that occurred between 1990 and 2005, which was positively affected by population growth, appears to be encouraging. “If this trend is sustained, Millennium Development Goal 6, to have halted and began to reverse the incidence of TB, will be achieved well before the target date of 2015,” said the report.

WHO officials said the slowing in the growth of TB in 2006 ushered in a “new era” in global efforts to eradicate the disease, but added that public health programs still need support.

“To make progress, firstly public programs must be further strengthened. Secondly, we need to fully tap the potential of other service providers,” WHO Director-General Margaret Chan, M.D., said in a written statement.

The statement noted that other studies have documented “that many patients are treated by private care providers, and by non-governmental, faith-based and community organizations, thus escaping detection by the public programs.”

“Enlisting these other providers, working in partnership with national programs, will markedly increase diagnosis and treatment for people in need.”

In some countries, programs that were having great success against TB have been unable to continue at the 2006 pace.

XDR-TB Coming to a Location Near You

U.S. cases in foreign-born patients on the rise.

By Bruce Jancin
Elsevier Global Medical News

KEYSTONE, Colo. — Epidemiological trends dictate that most physicians will increasingly encounter extensively drug-resistant tuberculosis in coming years, Dr. Charles L. Daley predicted at a meeting on allergy and respiratory disease sponsored by the National Jewish Medical and Research Center, Denver.


Since then, however, the annual number of TB cases among U.S.-born individuals has declined sharply, while the number of cases arising in the foreign born has remained constant.

As a result of these crisscrossing trends, in each year since 2001 foreign-born persons have accounted for more than half of all TB cases in the United States.

That’s an important epidemiologic factor, because most of the XDR (extensively drug-resistant) TB that’s been reported has been outside the United States. With more cases here coming from those areas, no surprise, we’re going to see more MDR (multidrug-resistant) and XDR-TB,” said Dr. Daley, head of the division of mycobacterial and respiratory infections at the center and professor of medicine at the University of Colorado, Denver.

The No.1 risk factor for MDR and XDR is foreign birth in areas where TB is endemic and TB control is poor.

Dr. DALEY

FDA MedWatch Alert: Spiriva May Be Linked to Risk of Stroke

Use of Pfizer/Boehringer Ingelheim’s chronic obstructive pulmonary medication Spiriva may be linked to stroke, the Food and Drug Administration said in a March 18 MedWatch alert.

According to the agency, manufacturer Boehringer Ingelheim conducted a pooled analysis of safety data from 29 studies of about 13,500 patients, and findings indicate that use of Spiriva (tiotropium bromide monoiodide) is linked to an excess risk of any type of stroke in 2 patients for every 1,000 patients taking the drug for 1 year. The company submitted the data from 23 studies of the Spiriva HandiFlo, and four trials of Spiriva Respimat, the formulation that is marketed in Europe.

The analyses showed an excess risk of stroke of 8 patients for every 1,000 taking Spiriva for 1 year, versus 6 patients for every 1,000 taking placebo.

“It is important to interpret these preliminary results with caution,” the agency said in an accompanying “early communication about an ongoing safety review” as it noted that it has “not yet confirmed these analyses.”

In fact, the FDA has requested additional information and is currently reviewing post-marketing adverse events reports with Spiriva.

The agency points out it will have data from Boehringer Ingelheim’s 4-year, long-term Spiriva trial, UPLIFT, in June, and that data likely will inform any ongoing review of potential risks. The FDA issued a safety notice in February alerting health care providers to the risk of stroke in patients taking Spiriva.

In the United States, roughly 46% of MDR-TB strains are XDR. In Russia, the rate is 14%.

South Africa is another hotbed of XDR. However, little TB drug resistance exists elsewhere on the continent. That’s because MDR-TB and XDR-TB are caused by inadequate treatment—most patients are put on ineffective therapy, and the majority of patients among whom the majority of MDR cases occur are foreign born from South Africa and other African countries. If patients do not receive adequate treatment, as the number of cases increases, drug resistance is increased.

“MDR-TB has been there since 1980, but XDR is a recent phenomenon,” the WHO’s Kilpatrick said Aug. 16 at a meeting on the epidemiology of MDR-TB. "It is emerging in many parts of the world, and typically --- about 2% per year. It is increasing. And in some cases we have examples of XDR-TB".
ACIP Recommends Flu Shots for School-Age Children

BY MIRIAM E. TUCKER
Eliver Global Medical News

ATLANTA — The unanimous vote by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention at its winter meeting adds the 5- to 18-year age group to the previous recommendations for children aged 6 months through 5 years. The new recommendation is “an important advance for children,” Dr. Joseph A. Bocchini Jr. said in an interview.

The vote for the expanded recommendation was unanimous, but the decision about when it should go into effect was not. Some ACIP members said that it shouldn’t become official until the 2009-2010 influenza season in order to allow time to prepare for implementation, while others felt that an immediate recommendation would get the ball rolling sooner. They ultimately voted for compromise language—the wording is subject to revision—that the recommendation should take effect “as soon as feasible, but no later than the 2009-2010 influenza season.”

Although there are few deaths or hospitalizations for influenza among school-age children compared with younger children, the elderly, or those with chronic conditions, children aged 5-18 years make five to seven outpatient visits per 100 children annually for influenza, and they often receive antibiotics. About 10-30 influenza illnesses occur per 100 children, resulting in high rates of school absenteeism. Dr. Anthony Fiore of the Influenza Division of the CDC’s National Center for Immunization and Respiratory Diseases, told the committee.

The recommendation also is expected to reduce transmission among adult contacts, and improve current low rates of immunization among the 50% of school-aged children who already have an indication for the vaccine because of a chronic condition or contact status. Data on cost-effectiveness of influenza vaccine in that age group suggest it is more expensive than many currently recommended vaccines but that “models do not fully account for potential indirect effects,” Dr. Fiore said.

The CDC is expected to follow the advice of the ACIP, which then must be “harmonized” with that of the American Academy of Pediatrics and other professional societies.

The AAP’s Committee on Infectious Disease will discuss the recommendation at its April meeting, said Dr. Bocchini, one of two AAP liaisons to the ACIP. He added that even with the language allowing a year’s leeway, many pediatricians won’t be able to start right away. “We recognize there will be significant potential impediments to getting this done, and most won’t be able to consider this until the 2009-2010 season,” said Dr. Bocchini, professor of pediatrics and chairman of the department of pediatrics at Louisiana State University Health Sciences Center in Shreveport, and chief of the section of pediatric infectious diseases and medical director of the Children’s Hospital in Shreveport.

But pediatricians aren’t expected to shoulder the entire burden. During the discussion, panel members agreed that broader approaches such as school- or community-based immunization programs will need to be developed in order to achieve the goal of immunizing all children every year during influenza season.

Dr. Kathleen Neuzil, who chaired the ACIP Influenza Virus Working Group, said that the decision to go forward at this time was based on the fact that there are no remaining critical data gaps, and no clear indication that more data will be available in the near-term on feasibility or indirect protection from influenza immunization to unimmunized contacts. Moreover, “There is no clear indication that steps will be taken to prepare in the absence of a recommendation.”

The working group’s document that was initially presented to the committee called for the recommendation to take effect beginning in the 2009-2010 season, primarily because many practitioners would have already ordered their vaccine supply for 2008-2009. Other reasons for waiting included the large number of new vaccine recommendations in the last 2-3 years, the need for education, and to allow time to harmonize with other professional organizations, said Dr. Neuzil of the University of Washington, Seattle.

Several panel members endorsed a cautious approach, but others urged the committee to move forward more quickly. Patricia Stinchfield, a nurse practitioner and director of pediatric infectious disease and immunology at the Children’s Hospitals and Clinics of Minnesota, St. Paul, said that most of the clinicians she works with are already offering influenza vaccine to all children. “They don’t feel fearful of a new implementation program. We have already ordered our vaccine, but we also know that at the end of every season we throw vaccine away.”

States Rapidly Adopting Newborn Screening for CF

BY TIMOTHY F. KIRK
Eliver Global Medical News

SALT LAKE CITY — Twenty-nine states required newborn cystic fibrosis screening as of this past summer, and more states are likely to do so soon, Dr. Michael Rock said at the annual meeting of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

“Cystic fibrosis newborn screening is really taking off across the country,” said Dr. Rock, director of the cystic fibrosis center at the University of Wisconsin, Madison.

The Cystic Fibrosis Foundation has called for newborn testing in every state by 2010. “We’re on track to meet that goal,” he noted.

The number of states requiring newborn screening has been increasing rapidly since 2004 when the Centers for Disease Control and Prevention issued a statement that expert opinion considered the health benefits of screening to outweigh the costs.

Since then, an advisory committee to the secretary of the Department of Health and Human Services recommended that all states screen for 29 conditions in newborns. One of those tests was the immune-reactive trypsinogen test for cystic fibrosis.

A study conducted on all children diagnosed with cystic fibrosis in Wisconsin between 1984 and 1995 showed that earlier detection resulting from newborn screening resulted in better growth for those children (J. Pediatr. 2005;147:S10-6), and other evidence suggests that earlier detection can affect cognition, if efforts are made to improve vitamin E status in diagnosed children (Pediatrics 2004;113:1549-58), Dr. Rock said.

The states that did not mandate cystic fibrosis screening as of this summer were Alabama, Hawaii, Maine, Nevada, North Carolina, Utah, and Vermont. Connecticut and Pennsylvania have pilot programs in which testing is offered at some hospitals, but do not have universal screening. And Massachusetts has a pilot program whereby hospitals offer testing, but it is not required.

States that had decided to mandate universal testing but had not implemented the requirement as of this past summer are Arizona, Arkansas, Florida, Kansas, Illinois, Indiana, Michigan, Montana, Tennessee, Texas, and West Virginia, according to Dr. Rock.

Screening for cystic fibrosis is very cost effective, Dr. Rock said. According to data from two studies, the cost of offering newborn screening is $2.66 per infant, and the estimated yearly cost of treating that infant with earlier diagnosis is $7,228. In comparison, the cost of conventional diagnosis is $4.97 per patient and the yearly cost of treating that patient is $12,008.

Dr. Rock had no financial conflicts of interest to disclose.

According to a recent study—the Newborn Screening Report Card—conducted by the March of Dimes, as of June 2007, 88% of all newborns received 21 or more of the 28 newborn screening tests recommended by the American College of Medical Genetics, up from just 38% as recently as 2 years ago.

ACCP Board Review.
The Proven Leader in Comprehensive Review Programs

Relay on the ACCP, the leader in board review curriculum for over 30 years, to bring you comprehensive review programs of proven success. World-renowned clinicians present exam-focused content to offer relevant board preparation courses that make best use of your study time.

Learn more and register: www.chestnet.org (800) 343-2227 or (847) 498-1400
Less Delirium Seen With Precedex During Extended ICU Trial

BY BETSY BATES
Elsevier Global Medical News

HONOLULU — The sedative dexmedetomidine (Precedex) was significantly better than midazolam (anorexic intensively mechanically ventilated patients in a randomized, double-blind trial assessing its long-term use.

In the study of 366 intensive care patients sedated with one or the other drug for 1-8 days, the daily incidence of delirium was 35% in the dexmedetomidine patients and 76% in the midazolam patients, with most of the difference occurring early. The total time in delirium was 70 hours in the dexmedetomidine group, compared with almost 95 hours in the midazolam group.

Dr. Richard Riker reported at the annual congress of the Society of Critical Care Medicine.

The Food and Drug Administration mandated the study in 1999, when dexmedetomidine was approved for sedating mechanically ventilated patients for a period not to exceed 24 hours at a maintenance dosage of 0.2-0.7 mcg/kg per hour.

Dr. Riker noted that practice registries suggest that “many of us are using the drug at higher doses and for longer durations than the current label [allows]. I think we’d all feel a bit better if we could bring the regulatory guidelines into [sync with] practice.”

However, he added, “I didn’t even begin to try to second guess the FDA.”

The choice of medication to sedate mechanically ventilated patients is a conundrum in the ICU, because commonly used agents are associated with a variety of adverse effects, including oversedation, paradoxical agitation, myocardial depression, hypotension, tachyphylaxis, bradycardia, and delirium.

Daily awakening reduces oversedation, but predicting and minimizing the other potential side effects in critically ill patients can be challenging, said Dr. Riker, deputy director of critical care research at Maine Medical Center Research Institute, Scarborough.

“There’s no perfect sedation out there,” he acknowledged, although he noted that any agent that can reduce delirium would be an important advance.

While the effects of 60%-80% of mechanically ventilated patients and is associated with prolonged cognitive impairment and a threefold higher mortality over 6 months.

The researchers randomly assigned 366 adult ICU patients in a 2:1 ratio to dexmedetomidine, a relatively selective alpha agonist, or midazolam, a benzodiazepine, at maintenance doses of 0.2-1.4 mcg/kg per hour and 0.02-0.1 mg/kg per hour, respectively.

The average age of the patients was early 60s, and there were slightly more men than women.

None of the women were pregnant. The subjects did not have unstable cardiac disease, burns, trauma, seizures or other central nervous system dysfunction, acute hepatitis or advanced liver disease, or dialysis-dependent liver failure.

Randomization occurred within 96 hours of intubation. The received dexmedetomidine and 103, midazolam. The groups were similar at baseline and there was no difference in the initial CAM-ICU scores.

Time within the target range of sedation—the primary efficacy endpoint for both the sedation and delirium arms—was very similar between the two groups.

However, patients assigned to dexmedetomidine had significantly less delirium than did those receiving midazolam. The daily incidence of delirium, which started out fairly equally at about 57% in patients of each group, remained almost steady in patients on dexmedetomidine at 54.6% but increased to 75.7% of patients taking midazolam, “likely reflecting the longer duration of ventilation and time in the ICU,” said Dr. Riker.

Time to extubation was abbreviated with dexmedetomidine: 94 hours vs. 138 hours, a 32% decrease in ventilator time.

Time to readiness for ICU discharge also was significantly shorter among patients assigned to dexmedetomidine: 6.2 days vs. 8 days for those receiving midazolam.

Nurses’ assessments showed that the patients taking dexmedetomidine were more communicative and cooperative, although both groups were judged to tolerate mechanical ventilation equally.

Both drugs were safe, although there were more treatment-related adverse events in the dexmedetomidine arm. Moderate to severe adverse events were similar in both groups.

As expected from previous trials, dexmedetomidine was associated with more bradycardia and midazolam was associated with more tachycardia. More infections occurred in patients taking midazolam, “likely reflecting the longer duration of ventilation and time in the ICU,” said Dr. Riker.

Dr. Riker disclosed that he has received grant support from a number of companies, including Hospira Inc., which manufactures dexmedetomidine and financed the FDA-mandated study.

 ICU Bedside Exams Inconsistently Done

BY BETSY BATES
Elsevier Global Medical News

HONOLULU — Fewer than half of critically ill patients received a physical examination from their bedside critical care unit physicians each day, Canadian researchers have found.

Patients seen first during rounds, those with higher Se- quential Organ Failure Assessment (SOFA) scores, and those not in isolation were more likely to be examined by their lead physicians during surrripicular line-of-sight observations of 193 patient/physician encounters, according to the findings of a study presented at the annual congress of the Society of Critical Care Medicine.

During multidisciplinary rounds, time spent at each ICU patient’s bedside averaged 8 minutes, with progressively less time spent on each subsequent patient in the rounding order.

The amount of time spent at the patient’s bedside increased with increased severity of illness, with the number of health professionals attending medical rounds.

Dr. Adel Al-Sarraf led the study at Sunnybrook Health Sciences Centre in Toronto, Ont., in which an impartial observer with critical care experience timed patient encounters and noted whether each ICU patient received a physical examination each day.

The busy academic medical center intensive care unit had a mean 95.6% occupancy during the study, with a ratio of medical to surgical patients of 3:1. Nearly half of the patients were mechanically ventilated, and 9% were in isolation.

The median Acute Physiology and Chronic Health Evaluation (APACHE) score for the study population was 19.6.

Lead physicians physically examined patients in 87 of 195 daily encounters, or 46.6%.

The duration of the primary ICU physician’s time at the bedside averaged 11 minutes, with 69 seconds spent on physical examination.

The first patient seen by the lead physician was 2.5 times more likely than the last patient seen to receive a physical examination.

Patients who were in isolation were almost 46 times less likely to be examined, while higher SOFA scores were found to slightly but significantly increase the likelihood of an examination.

A clinical experience increased, the likelihood of a lead physician conducting a physical examination decreased, with fellows being most lax, said Dr. Al-Sarraf.

During brief multidisciplinary rounds, just 8% of patients were physically examined.

Each patient seen during multidisciplinary rounds was seen for a shorter time than the previous patient was. When more health care professionals attended rounds, time spent at a patient’s bedside increased also true with a higher SOFA score.

Dr. Al-Sarraf concluded that “patient, caregiver, and ICU organization factors significantly influence bedside clinical examination and assessment practices.”

During the discussion following his talk, Dr. Al-Sarraf acknowledged that the study did not include any measures that would determine whether physical examinations correlated with improved outcome.

He said that this might be a fruitful avenue for future research, particularly because technology has taken physicians increasingly away from patients’ bedside.

Dr. Philip Marcus, FCP, comments: Rounding in the ICU has changed over the last few decades. Our focus has moved from looking for subtle changes in the physical examination to using technology to evaluate our patients for us. Indeed, with the advent of ICU care from a distant location (telemedicine) in order to provide 24/7 coverage, we rely on multiple set of eyes.

Of course, we need to keep the focus on the patient and not just the numbers generated. Also, patients in isolation have always suffered from being the last seen and, now we see, perhaps being “seen” at all.

THE FIRST PATIENT SEEN BY THE LEAD PHYSICIAN WAS 2.5 TIMES MORE LIKELY THAN WAS THE LAST PATIENT SEEN TO RECEIVE A PHYSICAL EXAM.

Dr. Philip Marcus, FCP, comments: Rounding in the ICU has changed over the last few decades. Our focus has moved from looking for subtle changes in the physical examination to using technology to evaluate our patients for us. Indeed, with the advent of ICU care from a distant location (telemedicine) in order to provide 24/7 coverage, we rely on multiple set of eyes.

Of course, we need to keep the focus on the patient and not just the numbers generated. Also, patients in isolation have always suffered from being the last seen and, now we see, perhaps being “seen” at all.
TBI Trials: Despite Setbacks, Promising Therapies Appear

Honolulu — Disappointing clinical trial results should not suggest that outcomes cannot be improved in traumatic brain injury, only that study methodologies may need to be refined and study populations equalized as promising approaches come to the fore, Dr. D. James Cooper said during a plenary address at the annual congress of the Society of Critical Care Medicine.

To be sure, meaningful advances have been elusive, with various interventions producing hopeful improvements in animal models, then fizzling in human trials.

But the heterogeneity of the traumatic brain injury (TBI) population and “huge differences” in the specific trauma suffered may make study results look unfairly pessimistic, said Dr. Cooper, deputy director of the intensive care unit at Alfred Hospital, Melbourne.

Experimental treatments may be initiated too late, often because of logistical and informed-consent dilemmas, and older patients may be so unlikely to benefit that they negatively skew results.

Follow-up assessment periods may be too brief, since it increasingly appears that Glasgow Outcome Scale scores improve greatly over time, but very slowly, he said.

A number of lessons have indeed been learned, even from negative clinical trials, and a number of promising approaches are currently under review.

Serious doubt has been cast on the efficacy of early high-dose steroids, for example, following the curtailment of the 10,000-patient randomized controlled MRC-CRASH (Corticosteroid Randomisation After Significant Head Injury) trial in the United Kingdom after excess deaths were reported in the steroid arm. “It’s abundantly clear... that the use of high-dose steroids should cease,” said Dr. Cooper, who also serves as associate director of Australia’s National Trauma Research Institute.

Because they lower vasopressor requirements in TBI patients, lower-dose steroids are used quite commonly in the intensive care environment, he noted. “There are no randomized controlled trials at all in this area, and it’s clear to me, based on the unequivocal MRC-CRASH results, that there needs to be... a reevaluation” of this practice, said Dr. Cooper.

Another unexpected finding came from the Australian SAFE-TBI (Saline versus Albumin Fluid Evaluation–Traumatic Brain Injury) study, in which Dr. Cooper participated. That study of nearly 500 patients confirmed that albumin is independently associated with mortality in TBI patients when it is used for intravascular fluid resuscitation in the first 28 days. In contrast, saline was associated with lower mortality and better neurologic outcomes in patients with moderate to severe TBI.

The reasons remain unclear, although Dr. Cooper hypothesized that albumin may increase brain edema, prompting the use of other agents that could contribute to mortality; that it may increase bleeding or cause more coagulopathy; or that it may be the result of hemodilution.

The possibility remains that albumin’s negative effect on survival may be a class effect of colloids, he said.

A recent analysis of data from both the SAFE-TBI study and the earlier ATBIS (Australian Traumatic Brain Injury Study) “[adds] to our strong feeling that saline alone might be worthwhile,” he said.

As a final note, Dr. Cooper outlined two ongoing international clinical trials of early decompressive craniectomy to reduce intracranial pressure, an approach he said may offer “considerable promise.”

The notion of temporarily removing the anterior portion of the skull is not a new idea, he stressed. But it has been controversial and not well studied, despite striking findings of benefit among young patients in small trials.

For example, the absolute risk of mortality was halved with early decompressive craniectomy versus medical therapy alone in a recent, 38-patient French study; but the trial was concluded early because of slow recruitment.

Dr. Cooper’s government-sponsored DECRA (Early Decompression Craniectomy in Patients With Severe Traumatic Brain Injury) trial at 21 international sites (including 2 in the United States) is enrolling only patients younger than 60 years old with blunt diffuse brain injuries—strict criteria that may be more conducive to interpreting results, he said.

Thus far, 112 patients have been enrolled of 165 anticipated, which is “already many, many times higher than the largest study ever conducted of early decompressive craniectomy,” Dr. Cooper noted.

In the first 42 patients randomized to surgery, the complication rate has been less than 10%, he said. While the trial is promising, Dr. Cooper urged colleagues to wait for study results in 2009 before implementing the procedure at their institutions.
Black Americans with chronic obstructive pulmonary disease were 17% less likely than whites to undergo lung transplantation after being placed on a waiting list, according to the results of a large retrospective study.

A review of records from a 10-year period showed that 61% of blacks and 68% of whites on a waiting list received lung transplants. The study also detected a 19% greater risk of death or removal from the waiting list among blacks compared with whites, in spite of similar lung function at the time of listing.

“These disparities are consistent with those observed among patients awaiting kidney and liver transplantation, and among patients with other advanced lung diseases such as pulmonary arterial hypertension and pulmonary fibrosis,” reported Dr. David J. Lederer and his colleagues at Columbia University, New York.

The investigators performed a retrospective cohort analysis of all non-Hispanic blacks and whites over age 39 with a diagnosis of chronic obstructive pulmonary disease (COPD) or emphysema who were placed on the United Network for Organ Sharing (UNOS) waiting list for lung transplantation in the United States between 1995 and 2004 (Ann. J. Respir. Crit. Care Med. 2008;177:450-54).

The researchers obtained dates of transplantation and removal from the list from the UNOS file, and determined deaths using the Social Security Death Master File and the UNOS data set. Analysis showed that after listing, 171 (61%) of 280 blacks and 5,572 (68%) of 8,277 whites received lung transplants. A total of 47 blacks (17%) and 804 whites (15%) died while waiting, and 39 blacks (14%) and 900 whites (9%) were removed from the waiting list.

“If those removed from the list, 13 of 39 blacks and 229 of 500 whites subsequently died,” they said, adding that at the conclusion of the study period, 23 blacks (8%) and 388 whites (7%) remained on the list.

“The most common reasons for removal from the list were ‘too sick to transplant’ (11 blacks and 149 whites) and ‘other’ (12 blacks and 131 whites).

In 1995, the median time on the waiting list for those who either got a transplant, died, or were removed from the waiting list was about 40 days. Blacks’ reduced opportunity for a transplant was significant, even after adjustment for age, gender, disease severity, socioeconomic factors, transplant center volume, and access to health care, said Dr. Lederer.

While we did not prove it in our study, one explanation for the lower transplant rate among blacks might be their higher rates of death and removal from the waiting list,” Dr. Lederer said in an interview. “Differences in insurance, socioeconomic status, and cardiovascular risk factors explained some, but not all, of the higher risk of death or removal from the waiting list.”

The investigators expressed concern about the finding that in this cohort of lung transplant candidates with COPD, the white-to-black ratio was 19:1, a considerably wider spread than the previously reported range of 9:1 to 11:1 for emphysema or chronic bronchitis.

Although confounding factors, reporting or misclassification bias, and random variation might explain this finding, one possible explanation is that blacks with COPD may not have accessed the lung transplantation waiting list as readily as whites during the study period, they said.

“It is apparent that over time, the mortality rate is increasing for blacks at a faster rate than it is for whites,” said Dr. Lederer, adding that whether a transplant improves the long-term survival of those with COPD remains controversial.

Still, patients with end-stage COPD should get on the list, because at that point, the assumption is that you’ve maxed everything out,” he said. “You’ve stopped smoking, you’re using oxygen and bronchodilators, you’re in a pulmonary exercise rehabilitation program, you’ve considered other experimental therapies, and you’ve considered or had lung reduction surgery.”

Study Examines Stage III Patients

Lung Cancer • from page 1

Dr. Margaretorita, a thoracic surgeon at Catholic University, Rome. To find out, Dr. Margaretorita and his associates assessed 80 patients with stage IIIa or IIb NSCLC downstaged to stage 0 or I by induction therapy. They compared the 3-year and 5-year survival rates in this group with 367 early-stage NSCLC patients scheduled for surgery only. Demographics were comparable between groups, he said.

Multimodal induction therapy included various chemotherapy protocols (for example, carboplatin, cisplatin/5-FU, or cisplatin and gemcitabine) and concurrent radiation. The 80 patients who responded were from a group of 226 patients treated with the induction protocol between 1992 and 2003.

Among the downstaged patients, 3-year survival was 48% and 5-year survival was 46%. Among the early-stage controls, 3-year survival was 82% and 5-year survival was 76%.

“This is an excellent study, elegantly presented,” said study discussant Dr. Douglas E. Wood, chief of general thoracic surgery at the University of Washington Medical Center, Seattle. “It has the usual limitations that a retrospective study might have.”

There may have been selection bias, for example, because the researchers included only patients who had surgery. On the other hand, its “enormous strengths include rigorous standardization of techniques, a great follow-up, and excellent clinical results.”

There was no difference in 5-year survival between the 44 stage IIIa and 36 initial stage IIb patients who responded to induction. Complication rates were similar between groups, Dr. Margaretorita said. All the cancer in the first group was locally advanced; no patient in either group had a nodal metastasis, he added.

Dr. Wood asked why the researchers included stage IIb NSCLC patients. “This was a selected group,” Dr. Margaretorita said. “The initial challenge from our oncologists was to include the IIb group.”

Despite the improved survival among the early-stage patients who had surgery without induction, Dr. Margaretorita said, “downstaging to pathologic stage 0 or I after induction therapy for clinical stage III non-small cell lung cancer significantly improves long-term survival.”

Dr. Michael Alberts, FACP, comments: “The most appropriate treatment for patients with stage III lung cancer continues to be a subject of great debate. This article reports encouraging results among patients with stage III lung cancer who were ‘downstaged’ with induction therapy prior to surgery. Questions remain, however, as to the best induction regimen, how to re-stage after induction, and how to treat those who were not ‘downstaged.’

Specialty Medicine. Specialty Codes.

New! 12th Edition

For a coding resource as precise and specialized as the medicine voupractice, turn to Coding for Chest Medicine 2008. The updated 12th edition includes detailed coding information for pulmonology, critical care, and sleep medicine and a new chapter on coding for sleep services. It’s the perfect resource for physicians, nonphysician providers, and administrative staff.

Member $125
Nonmember $310
Prepub $157

Don’t Miss These Upcoming Webinars

Critical Care Coding and Documentation Workshop (Wed., April 16)
Pulmonary Coding and Documentation Workshop (Wed., April 17)

Watch www.chestnet.org for details.

Don’t Miss These Upcoming Webinars

Critical Care Coding and Documentation Workshop (Wed., April 16)
Pulmonary Coding and Documentation Workshop (Wed., April 17)

Watch www.chestnet.org for details.

Reserve your copies today.

(800) 342-2277 or (441) 490-1400

American College of Chest Physicians

Hazard Ratios Show Race Discrepancy in Chronic Obstructive Pulmonary Disease

<table>
<thead>
<tr>
<th>Race</th>
<th>Non-Hispanic blacks (n = 280)</th>
<th>Non-Hispanic whites (n = 5,272)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transplantation</td>
<td>0.83</td>
<td>1.00</td>
</tr>
<tr>
<td>Death or removal from list</td>
<td>1.19</td>
<td>1.00</td>
</tr>
</tbody>
</table>

Note: Data adjusted for age, sex, transplant center volume, forced vital capacity %, forced expiratory volume, %, pulmonary hypertension, 6-minute walk distance, diabetes, hypertension, body mass index, private insurance, and poverty level.

Source: American Journal of Respiratory and Critical Care Medicine.
Radiofrequency Ablation Shows Promise in Lung Cancer

The rates of tumor progression were 10.4% at 1 year and 17.5% at 2 years.

By Miriam E. Tucker
Elsevier Global Medical News

Washington — Radiofrequency ablation resulted in 70% survival at 2 years in a study of 248 lung cancer patients.

"Radiofrequency ablation is minimally invasive, with a high local success rate. It is a curative treatment in nonsurgical patients," Dr. Thierry de Baere said at the annual meeting of the Society of Interventional Radiology.

The patients, 60% of whom were men and were aged 27–85 years (mean, 62 years), had a total of 397 tumors. Of those, 19% were primary non-small-cell lung cancer, and 81% were lung metastases (the majority from colon, rectum, or kidney).

Survival data were available in about 77% of cases; the rest of the patients had two or more tumors. Bilateral tumors were present in 23% of the patients.

All were treated with CT-guided radiofrequency ablation (RFA) using expandable needles. Of a total 301 RFA sessions (3.23 sessions per patient), all but 5 were performed under general anesthesia. The complication rate included 2% with tumors, said Dr. de Baere, an interventional radiologist at the Institut de Cancérologie Gustave Roussy, Villejuif, France.

Rates of local tumor progression were 6.1% per tumor at 1 year and 11.2% per tumor at 2 years. For tumors of 2 cm or smaller, progression rates were much lower—3.7% at 1 year and 8.2% at 2 years.

In contrast, for tumors larger than 2 cm, progression occurred in 12.4% at 1 year and 19.4% at 2 years. This 2-year survival difference between tumors measuring 2 cm or smaller versus those with tumors greater than 2 cm was statistically significant.

For patient, the rates of tumor progression were 10.4% at 1 year and 17.5% at 2 years. More than half of the patients (37.5%) had no viable lung tumors at 1 year, and 38.8% had no viable lungs tumors at 2 years.

Median survival was 25 months, with 88.7% of patients surviving at 1 year and 70.3% at 2 years. The proportion of patients without pulmonary evolution was 57.5% at 1 year and 38.8% at 2 years.

Survival was 66% at 1 year and 52% at 2 years in patients with primary lung tumors, compared with 54% and 35% in those with pulmonary metastases.

These results are similar to those of RFA studies conducted in the United States, and the 2-year survival rate is similar to that reported in surgical series, Dr. de Baere noted.

Pneumothorax, an expected side effect, occurred in 60% of the patients. Of those, 28% were merely followed without treatment, 30% were treated with aspiration under CT guidance, 12% had drainage, and fewer than 1% each required thoracoscopy or thoracotomy/resection.

Early complications included death in 0.5% (one patient, from ventricular fibrillation), pleural effusion in 5% (all minimal/mild), alveolar hemorrhage in 14% (11% minimal, 3% mild), and cutaneous burn in 1%.

After discharge from the hospital, 66% had no symptoms, whereas about one-third had at least one symptom, including pain/pleural effusion (23%), hemothysis (5%), pneumothorax (3%), and pneumomediastinum (2%).

Seven patients were readmitted to the hospital, none to the intensive care unit. Of those, two patients stayed just 1 day (both for pneumothorax), one for 8 days (pneumomediastinum), and three for 10 days (two with pneumothorax, one with pleuroscopy). One patient who developed sepsis was hospitalized for 34 days, he reported.

Dr. de Baere has received grant support from Covidien AG and honoraria from Boston Scientific Corp and Terumo Medical Corp.

Operating Room of the Future Already Here for Some Surgeons

By John R. Bell
Elsevier Global Medical News

A host of technological innovations in the operating room will give surgeons faster access to more information, reduce the chance of errors, cut complication rates, and likely decrease malpractice insurance costs, according to one surgeon whose hospital has built two “futuristic” ORs and plans to build others.

Advances in imaging displays, communication, lighting, and even the shape of the operating room will give surgeons access to information already available to day-to-day patients, Dr. Jeffery Milsom said in an interview about two such ORs at his institution.

More than 100 procedures have already been performed thus far in these innovative units, and four additional facilities (sometimes called smart ORs) are planned.

Each unit includes six large high-definition monitors that display a patient’s vital signs and allergies, all laparoscopic camera views, any external camera views, the electronic anesthetic record, and the names of all people in the operating theater. Such banks of monitors have long been a feature of mile-long law enforcement, and intelligence operations centers, Dr. Milsom noted.

The monitors allow the surgeon to interact, and one surgeon can be present from the waiting room, and even those sent by a pathologist or a referring physician, and to discuss them with the sender via a Bluetooth headset. Thus, for example, the surgeon can use a mouse and the high-definition monitor to pinpoint the precise area of a lesion to biopsy. Radiologic scans will also be available, via a secure archiving and communications system, he said. The accompanying software will allow video from the procedure to be streamed on the Internet or used in a live teleconference with other surgical staff.

The monitors also display checklists for each step in the procedure, with the option of an oral or written prompt for each. This system not only will help OR staff know instantly what comes next in an unfamiliar procedure but also will photographically document each step for future reference. “I’m planning photo documentation for standard operations as part of the operative record,” Dr. Milsom said.

The system will also eliminate most paperwork for the surgeon. “I think this will become mandatory in the future, he said, given the utility of such evidence in malpractice defense. In turn, he expects that eventual malpractice insurance costs will be reduced for institutions using such systems.

Dr. Milsom acknowledged that some surgeons have remained resistant to the new technology but added that most have not actually used the system. “There’s a certain difficulty when you change culture in a working environment,” he said. However, he added, “I’m pretty darn sure that, if we design these things right...people are going to fight to work in these rooms.”

The visual-imaging benefits of the future ORs are most useful for laparoscopic or minimally invasive procedures, but the other elements can benefit open surgery as well.

Malfunctions— which have been rare thus far, he said—have occurred only with the software. Hospital staff have been able to resolve the problems, although a 24-hour technical help line is available through LiveData Inc., maker of the visual display system.

Dr. Milsom said he has no financial relationship with any of the equipment manufacturers.

Training can be accomplished in a few weeks of daily sessions, although the actual time required will be affected by new features still in development. He estimated that a surgeon would need 5-10 hours of training time to become comfortable with the current systems.

The total cost to get a futuristic OR up and running is $200,000-$300,000 per room, Dr. Milsom estimated. His institution hopes to recoup cost of this by licensing the design of some of the systems developed there.

New features on the horizon include:

- Additional light sources on ceilings to give the surgeon more options for directing light to a certain area—but without the ungainly support booms. The lights will have high-intensity LCD sources and allow fingertip adjustment.
- A 3-D x-ray machine with a C-arm for imaging a body part on the spot (pending Food and Drug Administration approval).
- The use of automated floor scrubbers and strong jets of compressed air to allow faster sterilization and an environment less conducive to bacteria than what currently exists.

Dr. Milsom’s department is also looking at ways to eliminate unneeded equipment and cumbersome electrical conduits from the OR.

“Everything from the ceiling down to the floor I think is going to change dramatically,” he said. “The way a surgeon can and should operate has got to really undergo a lot of change for the betterment of the patient, the surgeon, and the whole working team.”

Dr. Milsom said that eventually every operating room in his hospital will be a futuristic OR. “When something’s really good, then people recognize it, and they don’t want anything else.”

Dr. Robert Cerfola, FCCP, comments: Dr. Milsom has presented a provocative and exciting concept of our future, and he probably is right. These ORs will eventually save money. However, the true cost savings of this incredibly expensive venture will be carefully weighed by hospital administrators after the costs of some of these are built. And given the already skyrocketing cost of medical care in the United States, the expansion of these units will be slow at best.
OSAH May Increase Risk of Motor Vehicle Crashes

BY KERRI WACHTER
Elsevier Global Medical News

P atients with obstructive sleep apnea hypopnea had a greater rate of motor vehicle crashes than did matched controls, and they were three times more likely to be involved in crashes when using personal injury, according to researchers in British Columbia.

“Our data indicate that the increased risk of motor vehicle crash occurs at all levels of OSAH severity,” Dr. Alan T. Mulgrew, of the University of British Columbia, Vancouver, and his colleagues wrote in an article in the journal Thorax published online.

The study involved 783 adult patients who were referred for overnight polysomnography for suspected sleep-disordered breathing.

Patients were excluded if they had symptoms of another sleep disorder known to cause daytime sleepiness (periodic limb movement disorder), or if they had another serious medical condition or overt psychiatric disease. They were also excluded if they were already being treated for OSAH.

Overnight polysomnography was performed using conventional instrumentation, and analysis was performed according to the American Academy of Sleep Medicine’s recommendations on syndrome definition and measurement techniques.

Patients completed a number of surveys on the night of their polysomnography study. Daytime sleepiness was assessed using the Epworth Sleepiness Scale.

All motorists in British Columbia are insured by a single insurance corporation: the Insurance Corporation of British Columbia (ICBC). Objective crash data for patients—including crash severity type—was obtained for 3 years prior to the sleep study.

All patients were matched with an individual control from the ICBC database based on age, gender, type of license, driving experience, and postal region.

Patients were categorized by OSAH severity based on the apnea hypopnea index (AHI): normal polysomnography (AHI of 5 or fewer events per hour), mild OSAH (AHI greater than 5 and up to 15), moderate OSAH (AHI greater than 15 but less than 30), and severe OSAH (AHI of 30 or more per hour).

Most patients (71%) were men, and the average patient age was 50 years. The average AHI was 22.6 events per hour, and the average Epworth Sleepiness Scale score was 10. The mean body mass index (BMI) was 31.8 kg/m². The average distance driven each week was 236 km (145 miles).

In terms of OSAH severity, 18% of patients had normal polysomnography, 30% had mild OSAH, 26% had moderate OSAH, and 26% had severe OSAH.

In all, there were 374 crashes, of which 251 (67%) happened to patients. In the patient group, 94 of 251 crashes caused minor property damage, 83 crashes caused major property damage, and 74 crashes caused injuries.

This compared with 48, 52, and 23 in the control group (Thorax 2008 Jan 30. [Epub doi:10.1136/ thorax.2007.085464]).

In comparison, patients without OSAH (AHI 0-5 events per hour) were at lower risk of motor vehicle crashes than were patients with OSAH.

The presence of OSAH was linked with a 3.0- to 4.8-fold increase in the rate of more severe motor vehicle crashes. Within the patient group, there appeared to be a dose-response relationship between OSAH severity and the rate of motor vehicle crashes involving personal injury. In patients with an AHI of 0-5, motor vehicle crashes involving personal injury accounted for 9% of crashes, compared with 37% in those with an AHI greater than 30. Conversely, patients with an AHI of 0-5, patients with severe OSAH were 6.1 times more likely to be in a crash involving personal injury.

In terms of subjective sleepiness, there was no significant difference in motor vehicle crash rates among the patient and control groups.

Controlling for BMI group, Epworth Sleepiness Scale, BMI, gender, age, kilometers driven, and use of alcohol, sedatives, or caffeine, the presence of OSAH increased the rate ratio for any motor vehicle crash to 1.22, though this was not statistically significant.

Notably, BMI and kilometers driven were both significant in the model. The presence of OSAH did increase the rate ratio for crashes causing personal injury to 3.67, which was also statistically significant.

“Caution should be exercised when assessing patient driving risk, and all patients with OSAH should be advised of potential risk,” the authors advised.

Sleep Apnea May Be a Risk Factor for Diabetic Retinopathy

BY SARA FREEMAN
Elsevier Global Medical News

G LASGOW, SCOTLAND — Preliminary research presented at the annual professional conference of Diabetes U.K. suggests that sleep apnea could be a risk factor for diabetic retinopathy.

Dr. Simon Merritt of the Sleep Disorder Centre at St. Thomas’ Hospital in London presented data showing that diabetes patients with severe retinopathy had significantly lower and more fluctuating levels of oxygen throughout the night than those with normal or near-normal retinal scans.

‘Sleep-disordered breathing occurs at the time when the blood levels of oxygen are most metabolically active and is likely to add to retinal hypoxia and therefore increase angiogenesis and vascular permeability,’ said Dr. Merritt.

A total of 120 patients with type 2 diabetes who had undergone digital retinal photography within the past 6 months were included in the study. Data were presented for both those with retinopathy and those with normal or near-normal retinal scans.

The average age of the patients was 60-61 years, and there was no significant difference among those with severe retinopathy and those with normal or near-normal retinal changes in terms of hemoglobin A1c level, body mass index, blood pressure, or duration of diabetes.

However, patients with severe eye disease were found to have significantly lower and more variable oxygen levels during the night than did the comparator group as measured by pulse oximeter.

The minimum and mean oxygen saturation was 72% and 93%, respectively, in patients with severe retinopathy, compared with 82% and 97% in those with normal or near-normal vision.

The mean number of times the oxygen saturation dropped by 4% or more per hour was 14 vs. 4 episodes, and 12.6% vs. 1.8% of the night was spent with an oxygen saturation of less than 90%.

Although not in the same league as more established risk factors for diabetic retinopathy, such as hyperglycemia and hypertension, Dr. Merritt suggested that sleep-disordered breathing should be added to the list.

“We’re living longer and we’re getting fatter, so the incidence of type 2 diabetes and indeed sleep apnea is increasing,” Dr. Merritt said. Data have suggested that 22% of patients with type 2 diabetes also have obstructive sleep apnea.

Within the next few months, data should be available on all patients included in the study, and perhaps then it can be considered whether all patients with type 2 diabetes or just those with diabetic retinopathy should be screened or even treated for sleep apnea.

If sleep apnea continues to be a risk for retinopathy in this larger group of patients, then the question of which patients should be screened and/or treated will be raised.

Screening all patients with type 2 diabetes would not be a realistic target, Dr. Merritt said, since there would be far too many people for the available resources.

He proposed that if a patient with type 2 diabetes is obese, regularly snores, and appears sleepy in the daytime, then screen for sleep apnea.

At the very least, such a patient should be seen by a chest physician because they are at high risk of developing cardiovascular disease.

Whether limiting screening to only patients with diabetic retinopathy would be of value remains to be seen.

In response to a question from an audience member regarding whether giving oxygen to retinopathy patients would increase complications, Dr. Merritt noted that ‘by treating sleep apnea, you would only be aiming to normalize the oxygen levels; you wouldn’t be providing supranormal partial pressures of oxygen.

Performing a treatment study may prove challenging, however, since this would involve treating a large number of asymptomatic patients with a continuous positive airway pressure device, Dr. Merritt explained.

“We have enough difficulty convincing patients who need it to use it, and it would be for a relatively long time,” Dr. Merritt added.

The study was funded by ResMed (UK) Ltd., which makes devices to correct sleep-disordered breathing.
Current NCI-Sponsored Screening Trials for Lung Cancer

Mass screening may reduce lung cancer mortality—or it might be an inappropriate allocation of resources.

Lung cancer is the deadliest malignancy, as it will cause approximately 162,000 deaths in the United States in 2008—more than the next four most commonly diagnosed deadly cancers (colon, breast, prostate, and pancreas) combined (Jemal et al. CA Cancer J Clin 2008; Feb 20, Epub ahead of print).

Overall, about 85% of patients with lung cancer die of this disease. Lung cancer usually remains clinically “silent” until it reaches an advanced stage, yet diagnosis at stage 1 is associated with survival rates that are reported to be as high as 60% to 90% with surgical resection. This has led to multiple efforts to screen patients for an early diagnosis.

There was no reduction in lung cancer mortality in the nonrandomized studies of chest radiograph screening prior to 1970. Randomized, controlled trials in the 1970s (three in the United States, another in Czechoslovakia) used chest radiographs with or without spumon cytologic studies; all of them failed to demonstrate a mortality benefit from screening.

There were more early stage (stage I and II) lung cancers in the screened populations; however, reanalysis of data at 20 years from the Mayo Lung Project again failed to reveal a mortality benefit, despite the excess of lung cancers found in the screened study arm.

This suggests an overdiagnosis bias, i.e., the excess cancers were biologically less aggressive, and deaths occurred from other causes rather than from the lung cancer itself.

Moreover, a recent analysis by the Cochrane Library (Manser et al. Cochrane Database Syst Rev 2007; 4: [no page number]) led to the conclusion that there is an 11% relative increase in mortality from lung cancer associated with frequent chest radiograph screening (relative risk, 1.11; 95% CI, 1.00 to 1.23) and that frequent screening might be harmful.

There have been other criticisms of the earlier chest radiograph lung cancer screening trials, including small sample size; contamination of the control group by the administered chest radiographs; and the possibility that there is a small, but clinically important, benefit from screening that was not detected.

Two different, but complementary, randomized, controlled trials screening for lung cancer are being conducted at the present time under sponsorship from the National Cancer Institute (NCI).

The first is a project designed to determine whether a screening program for prostate, lung, colon, and ovarian cancers (PLCO) will reduce mortality from each organ-specific cancer that is screened. A single posteroanterior (PA) chest radiograph is used as the screening tool for lung cancer in the PLCO study.

There are several important differences between the PLCO trial and earlier lung cancer screening trials. The PLCO trial includes women and people who have never smoked, and subjects in the control group are not screened with a scheduled chest radiograph.

Between 1993 and 2001, the PLCO trial recruited 154,934 individuals, aged 55 to 74, with 77,446 individuals in the intervention group. There was a near-equal number of men and women, and 51.6% of subjects were current or former smokers.

At our center, we enrolled 24,677 subjects, some of whom are now in their 15th year of follow-up. We are currently following 19,654 subjects after accounting for people who have dropped out or who have died.

This large population of subjects has required up to 27 full-time employees to perform the screening tests, as well as data entry, data analysis, and the other tasks involved with managing the information accumulated during the study. Even now, after screening has been completed, follow-up with the recovery of medical records, correctly abstracting the information, and ensuring error-free data entry requires a staff of 1 half-time and 10 full-time employees.

In the PLCO study, lung cancer screening initially included a baseline PA chest radiograph and three annual follow-up screenings PA chest radiographs for all participants in the intervention group; the protocol was changed so that only smokers (current or former) were offered the third follow-up chest radiograph. Compliance with screening was high.

ongoing analysis of the intervention groups by the administered chest radiographs; and the possibility that there is a small, but clinically important, benefit from screening that was not detected.

Two different, but complementary, randomized, controlled trials screening for lung cancer are being conducted at the present time under sponsorship from the National Cancer Institute (NCI).

The first is a project designed to determine whether a screening program for prostate, lung, colon, and ovarian cancers (PLCO) will reduce mortality from each organ-specific cancer that is screened. A single posteroanterior (PA) chest radiograph is used as the screening tool for lung cancer in the PLCO study.

There are several important differences between the PLCO trial and earlier lung cancer screening trials. The PLCO trial includes women and people who have never smoked, and subjects in the control group are not screened with a scheduled chest radiograph.

Between 1993 and 2001, the PLCO trial recruited 154,934 individuals, aged 55 to 74, with 77,446 individuals in the intervention group. There was a near-equal number of men and women, and 51.6% of subjects were current or former smokers.

At our center, we enrolled 24,677 subjects, some of whom are now in their 15th year of follow-up. We are currently following 19,654 subjects after accounting for people who have dropped out or who have died.

This large population of subjects has required up to 27 full-time employees to perform the screening tests, as well as data entry, data analysis, and the other tasks involved with managing the information accumulated during the study. Even now, after screening has been completed, follow-up with the recovery of medical records, correctly abstracting the information, and ensuring error-free data entry requires a staff of 1 half-time and 10 full-time employees.

In the PLCO study, lung cancer screening initially included a baseline PA chest radiograph and three annual follow-up screenings PA chest radiographs for all participants in the intervention group; the protocol was changed so that only smokers (current or former) were offered the third follow-up chest radiograph. Compliance with screening was high.

ongoing analysis of the intervention group includes lung cancer detection rates, patterns of care in the evaluation for lung cancer, the importance of abnormal results that are not suspicious for lung cancer, characteristics of the lung cancers in people who have never smoked, and differences between cancers that were detected by screening vs. cancers that were diagnosed in the intervals between screening.

The Data and Safety Monitoring Board members are charged with the responsibility to look for the primacy end result of mortality in the intervention (screened) arm and the control arm. At present, the investigators are blinded to these results, in order to avoid bias, while attempting to interpret the outcome of the study.

After the inception of the PLCO study, low-dose CT (LDCT) emerged as a more sensitive technique to screen for noncalcified lung nodules. Multiple observation studies generated enthusiasm that LDCT could detect smaller nodules than is possible with a chest radiograph, and that additional diagnostic-quality CTs and biopsies performed according to a strict protocol would lead to surgical resection with the intent to cure.

Indeed, survival from the time of diagnosis was excellent—projected to be up to 90% at 10 years from the initial diagnosis in one such study (Henschke et al. Radiology 2006; 239:1761).

The problem with this study, and other observational studies, is that survival from the time of diagnosis does not account for the phenomenon of lead-time bias.

Diagnosis of the lung cancer will be made at an earlier date by any successful screening test; if the disease is going to lead to death because of its biological behavior at a given future date, there will be an increase in survival without any effect on mortality from the disease being screened. This is what is meant by lead-time bias.

Cognizant of this phenomenon, the NCI decided to sponsor a randomized, prospective, controlled trial that will compare LDCT with a PA chest radiograph to detect early-stage lung cancer.

The control group in the National Lung Screening Trial (NLST) received a PA chest radiograph instead of no screening. The benefit of the PA chest radiograph was designed to answer the question of whether a chest radiograph provides a mortality benefit compared with no screening. In case there is an advantage demonstrated by screening chest by chest radiograph by the PLCO study, it was felt that denial of this potential advantage to the control group during their participation in the NLST could not be justified.

A total of 53,461 subjects were enrolled nationwide in the NLST. As with the PLCO study, a prodigious staff of 14 employees was needed during the screening phase for the 3,395 subjects that we enrolled at our center. We still employ four people to manage and ensure the accuracy of all data that are accumulated during the follow-up phase after the screening is completed.

Note that the end point chosen for the PLCO study and the NLST is mortality, not survival. This distinguishes both studies from the observational studies that report survival from the time of diagnosis as their most important outcome variable.

The PLCO study and the NLST are statistically powered to detect significant differences in mortality; if there are such differences. Both studies also are designed to eliminate the potential for overdiagnosis and lead-time bias.

Welch et al. (Arch Intern Med 2007; 167:2289) offer a more complete discussion of the problems associated with currently published observational studies that report survival as their end point. The results of the PLCO study are expected to evolve; for the NLST, the results may be reported by 2010.

Until then, the pulmonary community must not be misled by the many efforts to promote LDCT screening for lung cancer.

Until then, the pulmonary community must not be misled by the many efforts to promote LDCT screening for lung cancer.

Dr. Gene L. Colice, FCCP, Editor, Pulmonary Perspectives

Dr. Paul A. Kvale, FCCP
Division of Pulmonary and Critical Care Medicine
Department of Biostatistics and Research Epidemiology
Henry Ford Health System
Detroit, MI
Health Care Disparities: A Complex Issue

The presidential campaign, particularly the Democratic campaign, has come to be defined by the issues of the economy and the Iraq war. These issues have been paramount, with a subtext of gender and racial issues, but the issue of health care reform remains quite large.

A discussion of the health status of the American populace cannot get very far without mention of the uninsured or underinsured, of which many are poor, underserved, and minority. The problem of health disparities of the poor, minorities, and underserved has been well documented, but solutions for the disparities in health care are much more difficult.

Disparities in health and health care are substantial for many of the patients we see in the ICU and many with pulmonary and sleep disorders. The reasons for such disparities are frequently complex and poorly understood but include poor access to quality health care; health care provider shortcomings; difficult and poorly responsive systems of care; patient-related issues, such as poor adherence to therapy; and social issues, such as poor socioeconomic status.

As most of us know, there are substantial health and health care disparities in asthma care. A recently published study (Erickson et al. Arch Intern Med 2007; 167:1846) evaluates the factors contributing to asthma health care disparities by studying them in a setting of uniform access to care (Kaiser Permanent of Northern California).

The effect of race on asthma management and outcomes in hospitalized patients in such a large, well-regulated, managed care organization was prospectively studied over a 4-year period. Patients (678) were interviewed after hospital discharge, and information that included asthma history, health status, and socioeconomic status (SES) was obtained.

The authors found that black race was associated with a higher risk of ED visits (hazard ratio [HR] 1.93) and hospitalizations (HR 1.89). The findings persisted after adjusting for SES and differences in asthma therapy in blacks (eg, increased short-acting β-agonist use and increased peak flow meter use).

The authors concluded that even in a setting of uniform access to care, black race was associated with worse asthma outcomes, including greater risk of ED visits and hospitalizations. They showed that the association was not explained by differences in SES, asthma severity (asthma severity score), or asthma therapy.

They suggested that genetic differences might underlie the racial disparities, though they admitted that the reasons for the disparities in this study are not clear and are likely complex.

The authors acknowledged that unmeasured SES factors, comorbidity diseases, specific health-related behaviors, health care provider decisions, and patient behavioral and cultural beliefs were unstudied and may individually or in aggregate confound study findings. The authors also did not evaluate the possible role that difficult patient navigation of a complex system of care might have played in the disparate asthma care.

Despite the cited concerns, the study has helped clarify the role of health care access in asthma care. It is one of a number of studies that suggests that the problem of health care disparities (in asthma and many other diseases) is far more complex than one of inadequate health care access. It suggests that a far more comprehensive approach is necessary to overcome disparities in health and health care.

A recent monograph published by the Center for Health Care Strategies (Agnello and Somers, Issue Brief: From policy to action: addressing racial and ethnic disparities at the ground-level; Center for Health Care Strategies, August 2007) states that a comprehensive, multistakeholder strategy is needed to reduce racial and ethnic disparities in health care delivery. They further state that progress in this area requires the engagement of the entire health care stakeholder community, including purchasers, managed care organizations, providers, consumers (patients), and, importantly, community-based organizations.

It is clear that if we are to overcome health and health care disparities in this country, a comprehensive approach to health reform is necessary. Helping to resolve the problem of access to care (health insurance), as is being debated in the presidential campaign, will only be part of a very complex approach to health reform.

ACCP WORLDWIDE
An Annual Education Medical Mission in the Philippines

Submitted by the ACCP Philippine Chapter

Concurrent with the ACCP Philippine Chapter Annual Scientific Meeting (ASM) for the past 5 years, the chapter has held an Education Medical Mission (EMM) that targets a needy community in the locale where the meeting is held.

These two back-to-back activities coincide with the mission of the ACCP, to promote the prevention and treatment of diseases of the chest through leadership, education, research, and communication. Through the EMM, members of the ACCP who come from different parts of the country for the ASM are engaged to provide service to indigenous Thus far, these lung specialists have been very willing to volunteer and lend a hand.

This undertaking is not the same as the common one-time treatment activity. Partnership with a local physician group ensures follow-up and continuing care. Free consultation and medications are provided, and these serve as incentives for patients with preexisting pulmonary complaints to attend. The real thrust is to empower patients to manage their disease through acquisition of basic and practical knowledge and development of skills needed for treatment. These patients can then prevent and control risk factors and recognize early symptoms of worsening disease, and implement appropriate primary interventions when needed.

Long after the free medicine runs out, the knowledge learned and the skills acquired will continue to benefit these patients.

The mission specifically aims to:
1. Provide accurate diagnosis of the pulmonary condition.
2. Perform spirometry and other pulmonary function tests when indicated.
3. Give full courses of quality medicines and, if available, vaccines.
4. Give patients accurate and understandable information about their lung diseases through video presentations and interactive lectures.
5. Push advocates on tobacco control, smoking cessation, TB PPM directly observed therapy, basic infection control, guided asthma self-management, and more.
6. Teach patient pursed-lip breathing and other basic pulmonary rehabilitation maneuvers.
7. Develop patients’ skills in using inhalers, nebulizers, peak flow meters, and other devices whenever appropriate.
8. Identify patients with TB symptoms, and channel them to the local health center for microscopy and entry to the local TB program.

Indeed, by holding the ASM and the EMM outside metro Manila, the ACCP Philippine Chapter continues its efforts to improve patients’ lives and live up to its mission of being in the forefront of chest medicine.

This Month in CHEST: Editor’s Picks

- Portable Exhaled Nitric Oxide as a Screening Tool for Asthma in Young Adults During Pollen Season. By Dr. K. Kontikas, et al
- Ultrasound vs CT in Detecting Chest Wall Invasion by Tumor: A Prospective Study. By Dr. V. Bandi, et al
- Factors Associated With Failure to Complete Isoniazid Treatment for Latent Tuberculosis Infection in Rhode Island. By Dr. A. Kwara, et al
- Aerosolized Salbutamol Accelerates the Resolution of Pulmonary Edema After Lung Resection. By Dr. M. Licker, et al
- Definition of Cutoff Values for the Hyposia Test Used for Preflight Testing in Young Children With Neonatal Chronic Lung Disease. By Dr. A. C. Martin, et al
- Air Travel Hypoxemia vs the Hypoxia Inhilation Test in Passengers With COPD. By Dr. P. T. Kelly, et al
- Hypoxia Altitude Simulation Test. By Dr. C. J. Dinh, and Dr. M. E. Kreider
- The Hypoxia Altitude Simulation Test (Editorial). By Dr. L. C. Mohr, FCCP
- Affording EBUS (Editorial). By Dr. S. Manaker, FCCP, et al

www.chestjournal.org
The CHEST Foundation 2008 Awards

**Clinical Research Awards**
Reena Mehra, MD, FCCP, Assistant Professor at the University Hospitals of Cleveland/Case Medical School in Cleveland, OH, was the 2005 recipient of the American Board of Radiology (ABMR) Medical Student Award. The name of her research project was “Sleep-Disordered Breathing and Cardiac Arrhythmia: A Study of the Relationship Between Sleep Disordered Breathing and Cardiac Arrhythmia.”

**Humanitarian Project Development Grant**
Debra J. Romberger, MD, FCCP Nebraska Medical Center, Omaha, NE, was the recipient of the Humanitarian Project Development Grant in 2008. The name of her project was “One World Tuberculosis Control Program.”

**Funding from the CHEST Foundation Award**
Dr. Romberger has served as the co-director of the One World Tuberculosis Control Clinic since 1999. She and other dedicated volunteers and staff provide treatment for latent tuberculosis infection (LTBI) and as well active tuberculosis within the larger, first-generation immigrant population living in the Omaha area. About 350 patients have been treated at the clinic in the award year of 2006 to 2007.

Dr. Romberger states, “Funding from the CHEST Foundation Award were used to develop an ‘Express TB Visit’ model to answer the need to improve the completion rates for medical therapy for patients with LTBI. Patients with LTBI must complete 9 months of medical therapy and, generally, were failing to follow-up for all of their scheduled visits to receive medication. This new model for care delivery provides lower cost service in a more convenient manner for patients with LTBI cared for at our clinic.”

**Ambassadors Group News**
Meet the 2007 Poster Contest Winner: 11-year-old Natalie Gehred from Elm Grove, WI.

Natalie was in one of the classes in which Monir Almassi, an Ambassador Group volunteer, taught the Lung Lesson program last year. Natalie’s art teacher, Julie Stockinger, followed up Mrs. Almassi’s lesson with an assignment for her students to create a poster design that showed how to “Love Your Lungs.”

**Group Poster Design Contest**
Materials that Mrs. Almassi had distributed earlier at the school. Natalie’s design was selected to be the winner of the CHEST 2007 Poster Contest from the 35 entries that were received at The CHEST Foundation.

Natalie said, “I was extremely pleased and surprised to find out I had won the contest!”

**CheST Foundation 2008 Awards Program**

**Award Application Deadline: April 30**

- **Distinguished Scholar Award**
  - Second GlassSmith/Rowe Distinguished Scholar in Thoracic $160,000

- **Clinical Research and Leadership Awards**
  - Alpha-1 Foundation/CHEST Foundation Clinical Research Award in COPD and Alpha-1 Antitrypsin (AAT) Deficiency Award $25,000

- **The Association of Specialty Professors/CHEST Foundation Grant**
  - $100,000

- **The American Society of Transplantation/CHEST Foundation Clinical Research Award**
  - $120,000

- **The CHEST Foundation Humanitarian Awards**
  - $5,000

- **The Foundation Humanitarian Project Development Grant Awards**
  - $25,000

**Web site at www.chestfoundation.org**

-Natalie Gehred from Elm Grove, WI, submitted the winning entry in the CHEST 2007 Poster Contest.

Dr. Debra J. Romberger, FCCP, received an award.

The CHEST Foundation invites applications for the 2008 Awards Program. Please visit www.chestfoundation.org for more information.

**“The CHEST Foundation’s Clinical Research Traveler Award in COPD is allowing me to grow as an investigator, and am sure that it will greatly increase my capability of competing for future funding and a future academic position.”** — Nita Asero, MD, Loyola University Chicago

**“I am indebted to the CHEST Foundation and Ortho Biotech Clinical Affairs for their support of this project. They provided the resources I required to complete the study and develop my clinical research skills.”** — Robert West, MD, Children’s Hospital Medical Center

**Apply today at www.chestfoundation.org.**

-Award eligibility, application criteria, and payment options available. Visit The CHEST Foundation Web site for complete details.
Growth in Practice Administration, Investigating Health Care–Associated Infections

Members In Industry
Perspectives on Clinical Research, Careers, and More
The relationship between the pharmaceutical industry and health care providers has increasingly been the focus of discussion. The Members in Industry (MII) NetWork’s mission is to promote cooperation between the ACCP and industry and foster advances in clinical research and medical education.

The important topic of the interface between the pharmaceutical industry and the rest of the health care industry was discussed at CHEST 2007 in a session entitled, “Evolving Trends in the Relationship Between the Pharmaceutical Industry and the Health-Care Establishment.” The discussion was led by a panel that included ACCP Past President Dr. W. Michael Alberts, FCCP, representing academia, as well as two industry representatives, Dr. James Roach, FCCP, who gave an industry perspective, and Mark Wanda, who offered a viewpoint from government.

A related topic, “Working With the Health-Care Community in a Complex Compliance Environment,” was presented at the MII NetWork Open Meeting at CHEST 2007 by Dr. Mark Forshag, FCCP. This presentation is available for viewing on the MII Web site.

There was significant interest in the session, “Confronting a Career Change: Alternative Careers in Industry,” and in the Career Conversations table in ACCP Central, where MII steering committee members provided insight into pharmaceutical roles. A session exploring the impact of a product recall on physicians and patients was also successful. Many of these presentations will be available on the MII NetWork Web site.

The MII NetWork is excited about two sessions that have been accepted to the program for CHEST 2008, entitled, “Research Ethics and Oversight: Revolution, or Just Going Around in Circles?” and “The Drug Development Process: What is New?” If these types of topics interest you and you would like to become involved in the MII NetWork, contact networks@chestnet.org or visit the NetWorks Web site at www.chestnet.org/networks/accp_industry/ for more information.

Dr. Dawn Carlson, FCCP
Members in Industry NetWork
Vice-Chair

Practice Administration
The Growth of Practice Administration: More Than a Decade of Success
Is your practice manager one of the many physicians or administrative practice professionals who belong to the Practice Administration NetWork (PAN)? For more than a decade, PAN members have benefited from education, professional development, and networking within the ACCP. PAN members also have been integral to the expansion of several initiatives, such as the ACCP Practice Management Department. The PAN has provided postgraduate courses and educational sessions on practice management topics at CHEST since the mid-1990s.

Members of the NetWork have authored CHEST journal articles on important practice management topics, and many are contributing authors in the ACCP’s Coding for Chest Medicine 2008.

Recently, the NetWork and the College have formed a strategic alliance with the Medical Group Management Association to provide quality, statistically relevant data about pulmonary, critical care, and sleep practices. The NetWork, along with key members of the College, has successfully assisted in the RUC and CPT® process, which aims to protect and improve physician reimbursement.

Building a national network of pulmonary practice administrators and managers provides a mechanism to compare and contrast performance criteria, such as physician compensation, clinical operations, practice financials, and administrative structure. The PAN is looking ahead to future challenges in practice management.

Attracting new members strengthens the NetWork’s base of resources, benefits the College, and provides increased access to fellow practice managers with expertise in diverse disciplines. Members of the ACCP are encouraged to introduce their practice managers to the PAN.

For more information, contact Marla Brichat at mbrichat@chestnet.org, or visit www.chestnet.org/networks/practice_admin/index.php.

John Bauer, FACPMP, CPA, CFPE
Officier Steering Committee Member
Kim D. French, MHSA, CAPPM
Past Chair
Practice Administration NetWork

Respiratory Care
Payment System Brings Focus to Waterborne Health-Care-Associated Infection
Health-Care–associated infections (HAI) have a huge impact on morbidity, mortality, and medical expenditures. The Centers for Medicare & Medicaid Services have zeroed in on this problem and will deny payment for certain infectious complications and other complications of hospitalization. There is a renewed sense of urgency for health-care institutions to investigate the etiologies of HAI and implement effective measures to reduce the risk to patients.

Tap water is known to harbor potentially pathogenic microorganisms in health-care settings, where they may pose a substantial threat to patients. Waterborne microbes enter the health-care environment in a number of ways, including direct contact with water streams, aerosols from showers and faucets, and ice from ice machines.

Many waterborne organisms thrive in the biofilms that inevitably inhabit hospital water systems. Bacteria in biofilm also may display a higher degree of resistance to antimicrobial agents than planktonic bacteria. Microbes of clinical significance that may be isolated from water include Pseudomonas aeruginosa, Legionella pneumophila, Stenotrophomonas maltophilia, Acinetobacter spp., Klebsiella spp., arthro- mycrobacteria, Aspergillus fumigatus, and Fusarium solani.

Highest-risk populations include recipients of bone marrow and solid organ transplants, burn victims, patients who are undergoing chemotherapy, and patients in ICUs.

In addition, individuals with less recognized immunodeficiencies (eg, smokers with COPD) also may be at high risk of serious infections from waterborne pathogens.

Europe recognized the risk of waterborne HAI more than a decade ago and has widely adopted strategies, such as point-of-use (POU) water filtration, to reduce this risk.

Trautmann and colleagues (Am J Infect Control 2005; 33:541) demonstrated that, in the midst of a serious outbreak of Pseudomonas infections in their ICU, POU filtration resulted in dramatic, statistically significant reductions in Pseudomonas infections and cost.

POU filtration, when strategically employed in areas where high-risk patients receive care, offers substantial cost advantages over the additional treatment costs for HAI.

Dr. James M. Maguire, FCCP
Respiratory Care NetWork
Steering Committee Member
Dr. Joseph S. Cervia

Thoracic Oncology
It has been a busy year for the Thoracic Oncology NetWork: Diagnosis and Management of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) was released in September 2007.

The membership of the Thoracic Oncology NetWork played a pivotal role in the development and publication of these guidelines, which provide an excellent framework for clinicians dealing with patients with known or suspected lung cancer.

The Thoracic Oncology NetWork recently took part in a project that explored the variation in experts’ beliefs about lung cancer growth, progression, and prognosis. This brief report will appear in the Journal of Thoracic Oncology in the coming months.

The work being carried out by Dr. Michael Gould, FCCP, and colleagues at Stanford University will certainly help in developing decision-support tools for those faced with the dilemma of what to do with a solitary pulmonary nodule.

A second phase of this study will survey members of the Thoracic Oncology NetWork about their understanding and beliefs of the biology of lung cancer and how it may affect the way they manage patients.

The NetWork also has been busy assembling the content for the CHEST 2008 program. Some of the topics that will be covered are lung cancer in the older patient, lung cancer in nonsmokers, and the impact of gender on lung cancer.

There also will be an interactive tumor board and several sessions that will address the new clinical practice guidelines in lung cancer.

To find out more about how to become involved with the Thoracic Oncology NetWork, contact Jennifer Nemkovich at jnemkovich@chestnet.org.

Dr. Gerard A. Silvestri, FCCP
Thoracic Oncology NetWork
Chair
CMS Rules on CPAP Based on Home Sleep Testing

**PRACTICE MANAGEMENT UPDATE**

**CMS Rules on CPAP Based on Home Sleep Testing**

The 2005 National Coverage Determination (NCD) for Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA) was revised to allow coverage of CPAP based upon a diagnosis of OSA by home sleep testing (HST). The final NCD was published on March 13, 2008. ACCP had participated in the September 17, 2007, MedCAC meeting and has commented on the proposed guidelines, and ACCP President, Dr. Alvin V. Thomas, Jr., FCCP, advised CMS that additional research is needed addressing clinical outcome in a variety of age and ethnic populations.

The decision summary and full memorandum can be viewed at www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo.asp&id=2048. CMS commissioned two technical assessments (Home Diagnosis of OSA-Hypopnea Syndrome and Modeling Different Diagnostic Strategies) from the National Committee on Quality Assurance that can be reviewed in their entirety at www.cms.hhs.gov/mcd/viewtechassess.asp?id=204. The 2005 coverage decision for CPAP for OSA in the Medicare manual can be read at www.cms.hhs.gov/manuals/downloads/ncl01031_Part14.pdf. Highlights of the final NCD are:

- Coverage of CPAP is initially limited to 12 weeks for Medicare and Medicaid beneficiaries diagnosed with obstructive sleep apnea (OSA). The CPT code for CPAP is 94660 and the ICD-9-CM diagnosis code for sleep apnea (OSA) is 327.23. CMS assumes that the treating physician will assess the beneficiary and if sleep apnea is indicated by the clinical findings, appropriate sleep testing will be ordered, and the results will assist in the management of the condition to make or exclude a diagnosis of OSA.
- Tests not ordered by the treating physician and not furnished with the required level of supervision are not considered reasonable and necessary, and payable under the physician fee schedule. CPAP for adults is covered when diagnosed using a clinical evaluation and a positive: (1) polysomnography (PSG) performed in a sleep laboratory; or (2) unattended home sleep monitoring device of Type II; or (3) unattended home sleep monitoring device of Type III or (4) unattended home sleep monitoring device of Type IV, measuring at least 3 channels.
- A positive test for OSA is established if either of the following criteria using the apnea-hypopnea index (AHI) or respiratory distress index (RDI) is met. The AHI is equal to the average number of episodes of apnea and hypopnea per hour. The RDI is equal to the average number of respiratory disturbances per hour.

The criteria are:

1. AHI or RDI greater than or equal to 15 events per hour, or
2. AHI or RDI greater than or equal to 5 and less than or equal to 14 events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke.
- If the AHI or RDI is calculated based on less than 2 hours of continuous recorded sleep, the total number of recorded events to calculate the AHI or RDI during sleep testing is at least the number of events that would have been required in a 2-hour period.
- CMS deleted the distinct requirements that an individual have “moderate to severe OSA” and that “surgery is a likely alternative” as a condition for CPAP coverage.
- Clinical study requirements are further delineated in the NCD.

**2008**

**Future CHEST Meeting Dates**

- **October 31 - November 5, 2009**
  - CHEST 2009
  - San Diego, California
- **October 30 - November 4, 2010**
  - CHEST 2010
  - Vancouver, BC, Canada
- **October 22 - 27, 2011**
  - CHEST 2011
  - Honolulu, Hawaii

**ACCP-Sponsored Courses**

**ACCP-Endorsed Courses**

**Education Calendar**

Learn more about ACCP-sponsored and ACCP-endorsed educational courses.

www.chestnet.org/education/calendar.php

(800) 343-2227 or (847) 498-1400
Providing Quality Critical Care: The Past, Present, and Future

The Past

The history of critical care as a separate service demonstrates that it is still a fairly new concept in medicine and continues to evolve.

The modern construct of critical care started in Copenhagen during the polio epidemic in the 1950s. An anesthesiologist named Bjorn Bisen realized that skillful airway management and the positive-pressure ventilation required for treatment of patients with polio were similar to the requirements for an operating room. Working toward the goal of reducing mortality in these paralyzed patients with respiratory disease, anesthesiologists were the original leaders in critical care.

In the 1960s and 1970s, many technological advances allowed for more intensive monitoring. It is these advances, especially in cardiopulmonary diseases, and a more thorough appreciation of the complex pathophysiology, that first attracted internists into critical care.

In the later 1970s, efforts to formalize critical care training and eventual certification were attempted. The American Board of Medical Specialties (ABMS), with the four primary boards—medicine, surgery, pediatrics, and anesthesiology—tried to resolve this issue. This group was unable to form a consensus and was disbanded a few years later. At this point, the ABIM allowed each individual board to develop its own criteria and qualifications. The American Board of Internal Medicine (ABIM) administered the first examination in 1987 for added qualification in critical care.

The Present

During the 1990s, and into the 2000s, great growth was experienced and continues in critical care and its training programs. Many pulmonary divisions added the term ‘critical care’ to their titles.

Although anesthesia programs dominated early critical care training, the predominant route now is through a combined 3-year pulmonary/critical care fellowship.

Critical Care Institute
American College of Chest Physicians

Critical Care NetWork now has approximately 3,500 members registered and is the largest ACCP NetWork, just as the American Thoracic Society (ATS) Critical Care Assembly is its largest assembly. The ATS has changed its mission statement and journal name to include critical care.

In 2000, the ACCP Critical Care Institute was formally created to complement the Critical Care NetWork, with a focus on outreach and collaboration with other critical care professional societies. And, finally, the ABIM declared Critical Care a stand-alone specialty for certification in the spring of 2006.

The increasing demand for critical care and its providers has a multifactorial basis. In part, the catalyst for this increase in demand is the fact that patient outcomes have been affected by practitioner training.

A major factor driving this increased need, however, is the aging of the American population. The HRSA report for 2007 (www.cheesnet.org/practice/gr/hrsa.php). By the year 2020, the population older than 65 years will increase by 50%, and, by the year 2030, it is estimated to increase by 100%. In the United States, approximately 4 to 6 million people are admitted to an ICU each year, and there are about 6,000 ICUs across the country caring for approximately 55,000 people per day.

Critical care accounts for about 10% of all hospital beds, with an annual budget of about $180 billion, or 6.7% of the gross domestic product. About 18 million bed-days are used annually by critical care, and patients older than 65 years use more than 50%.

As a result of aging alone, the demand for intensivists would rise by 38% if all other factors remained the same. It is the changing paradigm in the delivery and organization of critical care that is also increasing the demand for trained staff.

Historically, there are three different delivery models in critical care: the open ICU; the mixed ICU; and the closed ICU. A recent review of services provided has designated them as low intensity vs. high intensity.

The open ICU, which is the traditional delivery system, has the primary attending with or without an intensivist deciding all aspects of the patient’s care. This low intensity model exists in two-thirds of the hospitals around the United States. About 500,000 people in the United States die each year in the ICU, and intensivists do not manage 360,000 of these patients.

In the high intensity models (mixed and closed), an intensivist provides all (closed) or some (mixed) of the critical care portion in collaboration with the primary attending. These models are only seen in one-third of US hospitals. It is estimated that 54,000 lives could be saved annually just by changing from a low intensity model to a high intensity model.

Multiple research papers have demonstrated that critical care provided by trained intensivists leading multidisciplinary teams consistently yields the best results (Pronovost et al. JAMA 2002; 288:2151). These teams consist of doctors, nurses, dietitians, pharmacists, respiratory therapists, and unit managers.

The results of these studies were so stark that private industry, attempting to maximize the return on their insurance dollars, created the LeapFrog standards (www.leapfroggroup.org).

In addition, in 2007, the Patient-Focused Critical Care Enhancement Act was introduced in the US Senate and the US House of Representatives. The ACCP as part of the Critical Care Workforce Partnership, worked closely with Senators and Representatives to get this bill introduced. Other members of the Partnership include the American Thoracic Society, the American Association of Critical-Care Nurses, and the Society of Critical Care Medicine.

The proposed legislation specifically addresses the critical care workforce shortage by calling for appropriations for research and projects that will take the first steps toward optimizing the delivery of critical care medicine (www.cheesnet.org/practice/gr/CCWorkforce.php).

The Future

In conclusion, presently recommended solutions fall into the following three categories: those that increase the efficiency of the critical care workforce, those that increase the critical care workforce itself, and those that address patient demand.

Methods suggested for increasing the efficiency of the critical care workforce

Continued on following page

By 2020, there will be a need for about 4,300 critical care providers.

This significant shortage will include doctors, nurses, pharmacists, and respiratory technicians.

There are over 2,000 critical care physicians in the United States now (self-reported). This number is expected to grow to about 3,000 by 2020. Even using two-thirds of critical patients as the target goal, by 2020, there will still be a need for about 4,300 providers. This significant shortage is not limited to doctors alone; critical care nurses, pharmacists, and respiratory technicians are in limited supply. Leading critical care societies identified this problem in 2007 (the COMPACCS Committee on Manpower for Pulmonary and Critical Care Societies and the Framing Options for Critical Care in the United States (FOCCUS) in 2004) outlined strategies to prevent a crisis in delivery of critical care.

In May 2006, the HRSA Report to Congress highlighted the disparity in supply and demand of the critical care workforce.

Most recently, the PROMIS conference proposed possible solutions to the critical care workforce problem (Baratto et al. Crit Care Med 2007; 35:1003).

In addition, in 2007, the Patient-Focused Critical Care Enhancement Act was introduced in the US Senate and the US House of Representatives.
ACCP President-Designate Honored by ACGME

Dr. Kalpalatha K. Guntupalli, FCCP, Chair of the ACCP Critical Care Institute and ACCP President-Designate, has recently been honored by the Accreditation Council for Graduate Medical Education (ACGME).

She was given the Parker J. Palmer “Courage to Teach” award “in recognition of extraordinary accomplishments in graduate medical education.”

Dr. Guntupalli is the fellowship program director for the Pulmonary/Critical Care and Critical Care fellowships at Baylor College of Medicine in Houston, TX.

This award is given to 10 training program directors. The winners are selected from nominations from training programs (residency and fellowships) in all specialties around the country. There are about 8,500 training programs in United States.

PRODUCT OF THE MONTH
Web Update on ICU Infections

View the newest ACCP product available online, which features audio tracks and faculty presentations from a CHEST 2007 satellite symposium.

This educational activity will update physicians on treatment protocols, therapeutic decision-making paradigms, and advances in the management of sepsis, pneumonia, and complex skin and soft tissue infections in the ICU.

To view this virtual satellite symposium, please visit the ACCP online education site at www.chestnet.org/education/online/index.php, and click on “Improving the Odds: Recognizing and Managing Complicated Infections in the ICU.”

Continued from previous page

include conducting research on optimal critical care delivery models; developing incentives to better distribute critical care providers; supporting alternative delivery models, such as a tiered critical care delivery system; increasing the utilization of technology through telemedicine initiatives and electronic medical records; increasing the effective supply of critical care providers through cross-training; and simplifying the currently cumbersome reimbursement system.

Methods suggested that addressing patient demand includes increasing support for critical care research in the elderly population; exploring alternative care pathways for elderly patients with high mortality conditions; and developing a patient-education campaign to teach Americans the benefits and limitations of critical care medicine.

None of these methods alone can avert this potential crisis. The only reasonable solutions will involve a collaboration among physicians, our patients, and the government.

Dr. Peter Sipio, FCCP
Assistant Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Head, MICU
Harlem Hospital Center
New York, NY

NOW SHOWING on chestnet.org
Updated Web Pages for the Interventional Chest/Diagnostic Procedures NetWork
www.chestnet.org/networks/icdp/

SEEK and find the best-selling review program

ACCP-SEEK is a comprehensive, self-study review tool based on the content blueprints from the Critical Care Medicine and Pulmonary Disease subspecialty board examinations. Each volume features 200 questions to test your recall, interpretation, and problem-solving skills. Questions are case-based, using patient histories, lab workups, and diagnostic images. The answer key provides a thorough discussion for each correct and incorrect answer, so you fully understand the topic.

Use ACCP-SEEK to:
Study for board exams.
Review critical care or pulmonary medicine at your convenience.
Earn up to 50 hours of CME credit.

SEEK your best-selling review program today.
www.chestnet.org
(800) 343-2227 or (847) 498-1400

Critical Care Medicine
Volume XVI
Editor in Chief: Stephanie M. Ayers, MD, FCCP
Deputy Editor: Joseph E. Pannillo, MD, FCCP

Pulmonary Medicine
Volume XVII
Editor in Chief: Mark J. Rosen, MD, FCCP
Deputy Editor: Ronald F. Goldman, MD, FCCP
Tampa — A patient's request for a hastened death—either an explicit request or a subtle one—should be considered a clinical emergency that offers an important therapeutic opportunity.

"When you're in the office and somebody asks, 'Doctor, will you help me die? I just want to end it all,' that is a true clinical emergency," Dr. Ira R. Byock said at the annual meeting of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association.

"It's as if somebody develops crushing chest pain or fibrillates and codes in your office. Somebody's life is at risk here. That person may have a progressive illness, but that doesn't mean that [his or her] life is at any less risk or that it's any less of an emergency," said Dr. Byock, who is director of palliative medicine at Dartmouth-Hitchcock Medical Center in Lebanon, N.H. Such a request is a "remarkable therapeutic opportunity," he said. "The very fact that the patient has shared this with you . . . opens up a therapeutic window."

Occasional thoughts of suicide or a desire for death are fairly common among people with serious, terminal illnesses.

In Oregon—where physician-assisted suicide is legal in certain circumstances—65 prescriptions for lethal medications were written in 2006, and 46 people died by lethal prescription that year (out of a total of roughly 31,000 deaths in the state). The 1997 Death with Dignity Act allows terminally ill Oregonians to end their lives through the voluntary self-administration of lethal medications, prescribed by a physician expressly for that purpose.

"Certain diagnoses are particularly associated with requests for assisted suicide and receipt of a lethal prescription," Dr. Byock said. Based on data through 2006 in Oregon, patients who have amyotrophic lateral sclerosis are about 35 times as likely to use a physician-assisted suicide or to ask for a lethal prescription as do patients with chronic obstructive pulmonary disease, he said. HIV/AIDS and cancer also are particularly associated with a request for assisted suicide and receipt of a lethal prescription.

Research also has shown that many terminally ill people meet diagnostic criteria for major depression, which is an important risk factor for a request for suicide. "In treating depression, I think we often just reach for the SSRI (selective serotonin reuptake inhibitors) or the psychostimulants, all of which can be valuable," Dr. Byock said. But don't forget to look for other causes of the depression, such as hyperthyroidism, adrenocortical function, or the side effects of other medications.

And because many of the somatic symptoms of depression—including fatigue, amnesia, anorexia, energy loss, sleep disturbance, and mild confusion—are common in terminal illness, the psychological symptoms are more useful in identifying depression in these patients. Look for hopelessness, helplessness, guilt, worthlessness, loss of meaning, and preoccupation with death and suicide.

Beyond that, the feeling of hopelessness has been shown to be more highly correlated with suicidal ideation in these patients than is depression. Think about recommending counseling to help patients address issues of hopelessness and helplessness.

Exposes a patient with advanced illness asks for help dying, it's important for physicians to recognize their own emotional responses to such requests. At the same time that a physician is moved by the patient's suffering, "at times, to a physician's ear, the expression of a wish to die can sound to us like a condemnation of our care," Dr. Byock observed. Acknowledging this is part of the therapeutic challenge.

The fact that the patient makes such a vulnerable statement is testament to the patient's trust in his or her physician. The most important thing a physician can do in these situations simply is to listen—an act that has therapeutic value in itself. The act of listening "helps people feel acknowledged and helps them feel like you're accompanying them on this difficult journey."

"Even if one is deeply, morally opposed to assisting a patient in suicide, it is possible and essential to be able to listen to the requests and accept the patient's feelings in a nonjudgmental manner," Dr. Byock said. "Showing empathy—with comments such as 'I can't imagine how hard this must be for you'—can also help to strengthen the therapeutic relationship, 'which is itself a powerful tool for treatment,' he said. It's important to clarify a request for death, as many patients are confused about end-of-life care. Some assume that by not accepting every possible treatment—anti-biotics and dialysis, for example—they are essentially committing suicide.

"We can often alleviate their anxiety and help them distinguish between actively shortening these lives and simply not using medical treatments that aren't consistent with their preferences and desires," said Dr. Byock.

Even simply informing patients that they can decline medically administered nutrition and hydration to allow a "natural" death can satisfy their concerns.

Sometimes patients won't directly express a desire for death but will hint at it or make deliberately provocative statements. One of Dr. Byock's patients told him that, "they should dig a hole and just shoot me.

Statements like these are valuable openings because they express the patient's fears and feelings, he said. They are also a way for patients to test their physician. 'If we respond 'oh, don't talk like that,' we've given a strong message,' he said.

Patients also may use provocative statements like, 'I hope you'll help me die when it's time' as a way of assessing their doctor's commitment to not letting them suffer. What may sound like a request for death could "simply be a desire to be assured of a way of escaping suffering if it becomes unbearable," he said. "It's important to understand whether they're referring to assisted suicide/terminally just adequate analgesia," he said.

In treating pain in this patient group, Dr. Byock recommends making it explicit to the patient, in the chart, and to medical colleagues that there needs to be a detailed pain management plan in place, with lots of contingencies, in case pain gets out of control.

This means taking a multimodal, layered approach using patient-controlled analgesia and scheduled, as necessary, and crisis medications. It's also important for patients to have specific telephone numbers to call after hours to get a prompt response.

"We pursue symptom-directed treatments even when the patient is ill," Dr. Byock said. These patients may benefit from regional blocks, axial analgesia, or neurolytic procedures.

In addition, it's a good idea to get a formal consultation with palliative care or pain services. Dr. Byock tells his patients that there always is the option of palliative sedation if no other options are working and pain is unbearable. "This is not only ethically acceptable, I would assert that it's ethically required, if nothing else is working," he said.

Another issue is that many patients with advanced illness is the worry about being a burden on their families or caregivers. Dr. Byock tells his patients that although they can't take away the burden, their behavior and attitude can influence how their families respond to them. "The way people die stays in the minds and hearts of those they leave behind," he said.

"When a patient with an advanced illness is the worry about being a burden on their families or caregivers. Dr. Byock tells his patients that although they can't take away the burden, their behavior and attitude can influence how their families respond to them. "The way people die stays in the minds and hearts of those they leave behind," he said.

Patients who have children can provide a model for their children and grandchildren of living with dignity to the very end of life. A patient can be reassured that this, "has value in and of itself," said Dr. Byock.

A Hastened Death Request Addressed

One of Dr. Byock's patients, Mr. B, was a 68-year-old man with colon cancer that had metastasized to the liver, lungs, and bone. He presented with increasing, severe left hip pain after a minor injury. He was on hydrocodone/acetaminophen (Vicodin) every 4 hours for pain relief. He was very anxious, and at times seemed unable to understand the information given to him, Dr. Byock said. Mr. B had retired after a career in industry. "He was a gentle, well-mannered man. His passions included walking in the wilderness and garden- ing, interests that he shared with his wife of 22 years," Dr. Byock recounted.

According to Dr. Byock, Mr. B volun- teered that he had been thinking about "ending it all." He spoke of a neighbor who had committed suicide by gunshot to the head because of severe cancer pain. "I don't want to end up like that. I hope you will help me die before I get to that point," Mr. B told his physician.

While hospitalized for the hip pain resulting from the minor injury, he was treated with long-acting mor- phine, an NSAID, and loznganep for his anxiety. A geriatric psychiatrist on the hospital staff was consulted about Mr. B's desire to die. Mr. B told the psychiatrist that he was feeling fine at the moment but he was in fear of being in constant, uncontrollable pain. He added that he knew his wife would be devastated if he committed suicide. When Dr. Byock learned that the real problem was fear of pain, he was able to reassure Mr. B that he could achieve sufficient pain control to live a high-quality life at home.

Mr. B was started on mirtazapine for depression, and his anxiety decreased during the course of his hospital stay. The medication also helped his sleep and appetite.

Before he went home, he was counsel- led about his pain management plan and assured that there was no circumstance in which he would suffer for more than a very short time.

Mr. B still talked about suicide when asked by a member of his palliative care team, but he no longer brought up the subject. He said that his feelings hadn't changed but that he felt more confident that he wouldn't have to turn to suicide. Dr. Byock said. He died at home in hospice care several months after he was discharged.
Tread Carefully With Palliative Sedation to Unconsciousness

BY KERRI WACHTER
Elsevier Global Medical News

Tampa — Palliative sedation to unconsciousness can be an option for terminally ill patients, but its use should be reserved for experts in palliative medicine.

“This is a big deal when you do this, in my opinion, and should be relatively rare,” said Dr. Timothy E. Quill, director of the center for ethics, humanities, and palliative care at the University of Rochester (N.Y.) Medical Center.

Palliative sedation to unconsciousness is “for unusual circumstances when suffering is so hard to control and so great that you decide, as a team, to try to relieve it,” Dr. Quill said.

In our review of the literature, these [types] are drastically confused,” Dr. Quill said.

The position statement defined the three levels of sedation as follows:

- **Ordinary sedation.** This includes the use of sedative medications for the treatment of anxiety, agitation, depression, insomnia, or related disorders. The goal is symptom relief without a reduction in the patient’s level of consciousness.

- **Palliative sedation.** This is the use of sedative medication, at least in part, to reduce the patient’s awareness of distressing symptoms that are not adequately controlled by symptom-specific therapies. The level of sedation should be proportional to the patient’s level of distress. Alacrity is preserved as much as possible.

- **Palliative sedation to unconsciousness.** This is the administration of sedatives to the point of unconsciousness, when less than adequate sedation has not achieved sufficient relief of distressing symptoms. This practice should be reserved for the most severe and intractable suffering at the very end of life.

With all three levels of sedation, the intent is to relieve suffering in a way that is proportional to the severity of suffering. This means that if you’re going to sedate someone to unconsciousness, the level of suffering needs to be pretty profound and unrelievable,” Dr. Quill said.

Palliative sedation to unconsciousness requires informed consent, which must come either from the patient or from the patient’s surrogate, he added.

When treating severe and unremitting physical pain, “we do need to give some consideration to the doctrine of double effect,” said Dr. Gregg K. VandeKieft, who is in private practice in Olympia, Wash.

Medical ethicists describe the following four components of the doctrine of double effect:

- The act itself must be good or at least morally neutral.
- The bad effect may be foreseen but is not intended.
- The bad effect must not be a means to the good effect.
- The need for the good effect outweighs the weight of the bad effect.

In the case of a patient with severe, unremitting pain, the good effect is pain control. The bad effect of shortening the patient’s life is a foreseen but not intended consequence. The intent is to relieve suffering, not to shorten life, and the relief of suffering is not achieved by death but by sedation. Lastly, this action is considered only after all other options have been explored.

“You can fall into the trap of prolonging a patient’s suffering, to exalt the other option, because of our moral discomfort, as opposed to what the patient truly needs,” Dr. Van deKieft said.

One audience member asked about ending pain versus ending suffering.

“I would argue that it’s not a semantic distinction, but rather that pain versus suffering are two very different [phenomena],” Dr. Van deKieft said.

Pain is a biomedical phenomenon, whereas suffering has biological, psychosocial, and cultural components, even spiritual components. Pain is not the sum total of suffering.

In discussing a clinical case, Dr. Mark V. Johnson, a psychiatrist who specializes in palliative care for Kaiser Permanente Medical Group Inc. in Sacramento, asked whether it’s acceptable for the medical team to bring up the issue of palliative sedation to unconsciousness if the patient or the patient’s surrogate has not already done so.

“The audience generally found that scenario acceptable, with one audience member stating, ‘informed consent for whichever course of action would supply that you’ve got to give them all of the different options. So you have to bring it up; you’re obligated to bring it up.’”

Dr. Blum agreed, likening the situation to dealing with coronary artery disease detected by angiography. All treatment options are offered: angioplasty, bypass, medical management.

Dr. Blum also asked the audience if surrogate decision makers can choose palliative sedation even if the patient had not considered this option. In general, the audience found this acceptable. One audience member suggested that the palliative care team really has not done its job properly if a surrogate must consider palliative sedation in the absence of a previous discussion of the subject with the patient.

Dr. Blum noted that he doesn’t bring the subject of palliative sedation up with every patient. But he tells patients who have a significant symptom burden that palliative sedation is an option to ensure that they don’t suffer too much.

Dr. Gary A. Johanson, of Memorial Hospice and Palliative Care Center in Santa Rosa, Calif., described a case involving the question of using palliative sedation to unconsciousness to control physical symptoms other than pain (for example, nausea, retching, and weakness) and to ease existential suffering (such as distress about the thought of death itself, or worry about being a burden to family and caregivers).

In such cases, the amount of time that the patient is likely to live can be an important consideration. If a patient who just had lumbar surgery is suffering a lot from back pain and has 40 years left, the situation is different than it would be for a patient who has only 3-4 days left and is classified as NPO (nothing by mouth), Dr. Johanson said.

One audience member asked what to do about a patient who is experiencing only existential suffering.

“If you are contemplating sedating such a person to unconsciousness, for sure that is a case where you get a second palliative care consultant, and an ethics consultant, and a psychiatric consultant, because you are way out on the edge,” Dr. Quill said.
PROFESSIONAL OPPORTUNITIES

Faculty Positions at the Assistant, Associate, or Full Professor Level

The Division of Pulmonary, Allergy and Critical Care Medicine in the Department of Medicine at the University of Alabama at Birmingham (UAB) invites applications for faculty positions at the Assistant, Associate, or Full Professor level. These positions will either be tenure track or tenured Faculty positions based on experience. The applicants must be MDs with training in Pulmonary and Critical Care Medicine. This position requires an interest in asthma or allergy and related clinical research. This individual will be asked to manage an Asthma or Allergy Clinic 1/2 days per week. Candidates must have strong written communication skills and will work with the UAB Lung Health Center on asthma and allergy clinical research. Candidates will have abundant opportunities to interact and collaborate with both basic and clinical scientists. Candidates should send a letter of interest, CV and a description of his/her research experience to: James E. Johnson, M.D., Interim Division Director, Division of Pulmonary, Allergy and Critical Care Medicine, THT-422; 1900 University Boulevard; Birmingham, AL 35294-0006. The University of Alabama at Birmingham is an Affirmative Action/Equal Opportunity Employer and welcomes applications from qualified women and minorities.

Pulmonary and Critical Care Physician

Established Pulmonary, Critical Care, and Internal Medicine Practice next door to one of America’s 50 best hospitals, currently has an opening for a Board Certified or Board Eligible Pulmonary and Critical Care physician. Board Certification or Board Eligibility in Sleep Medicine is desirable but not mandatory. This is a salaried position with growth potential for partnership, and opportunity to develop personal interests within practice. Our medical suite is located blocks away from many exciting urbanization projects developing in the downtown Los Angeles community. If interested please contact Nicole at 213-977-4979. Fax # 213-977-0544 and email: callung@aol.com

NORTH CAROLINA
PULMONOLOGIST

Assume practice in, family community located less than two hours from Carolina beaches, Charlotte, Raleigh and just 35 minutes from golf resort of Pinehurst. Loan repayment assistance possible. To learn more contact Melissa Ciarrrocca at 800-764-7497; Fax: 910-276-0470 or email: Melissa.Ciarrrocca@scotlandhealth.org Website: www.scotlandhealth.org

Pulmonary/Critical Care
Austin, Texas

Austin Critical Care Specialists seeking 4th BC/BE Critical Care physician to join rapidly growing practice. Enjoy the benefits of a small group practice with the support of an established multi-specialty administrative team. Generous compensation package with 401k, sign-on bonus and partnership eligibility. Austin is ranked in the “Top 10 Per-ferred Metropolitan Areas for Job Retention” based on 2007 survey from Monster.com. To find out more, contact Lynn Sprinkle, RN at lynn@accdocs.com or 512-610-0321.

BC/BE Intensivists

Prestigious pulmonary/critical care group practice seeking BC/BE intensivists for 24 hours/7 day in-house intensivist service for Chicago-area community hospital. This is a state-of-the-art facility in an attrac-tive northwest suburb. We offer excellent compensation and benefits, including health and generous retirement programs, malpractice coverage and tail. Sorry, no J1 visas. For further information, please email CV and cover letter to sweeneyman@chestmd.com or fax to 773-935-2724.

Intensivist Opportunity

NEW YORK – 40 MILES FROM NEW YORK CITY - Intensivist opportunity at leading Medical Center on desirable South Shore. Ideal coastal location, beautiful homes and excellent schools. Strong stable employee status, attractive compensation and benefit package. Full support staff. For details, contact Jennifer Mosher, Alpha Medical Group, 800-584-5001 or jmosher@alphamg.org

BEAUTIFUL COAST OF MAINE

BC/BE Pulmonologist

Multi-specialty, community hospital seeks full-time physician for outpatient practice. Beaufort is safe and offers beautiful views of Penobscot Bay. Ideal for outdoor enthu-siasts. Family oriented with excellent schools. Immediate availability. Contact Mark Biscone, Executive Director Waldo County General Hospital, PO Box 287, Beaufort, ME 04916, 207-338-9302 E-mail: mao@wch.com Website: www.wch.com

North Carolina

The Pinehurst Medical Clinic is seeking third and fourth BC/BE Pulmonary/Critical Care physician to join its 50 physician practice. BC/BE in Sleep Medicine a plus but not required.

Consider this:

➤ Enjoy compensation well in excess of 90th percentile nationally
➤ Call schedule of 1:4
➤ Two-year partnership track with low buy-in
➤ Fee buy-in to real estate corporation
➤ Group has 18 internists and a growing hospitalist program
➤ On-site Sleep Lab, PFT and CT service
➤ Practic has electronic medical records system and PACS
➤ Modern, 400-bed hospital (rated top 100 in country) with 40 ICU beds (located right across street from clinic)

This is a wonderful opportunity to join a premier multispecialty practice in Pinehurst, North Carolina. Pinehurst and the surrounding area is a sophisticated community with great schools, family activities, shopping, dining, horse country and world-class golf. Easy access to major metropolitan areas.

Pinehurst Medical Clinic, Inc.
Serving the Sandhills of North Carolina since 1956

For additional information contact: Bill Edwards, Chief Executive Officer 910-295-9218 bedwards@pinehurstmedical.com www.pinehurstmedical.com

Sorry, no visa opportunity available.

Best Readership, Low Cost Qualified Leads

2008

Chest Physician Rates
4 Column Classified Ads
From 1” to 12”
Sizes from 1/48th of a page
to a full page

FOR DEADLINES AND MORE INFORMATION CONTACT RHOUSA BEAVER
Tel: 443-512-8899 ext 106
Fax your ad to 443-512-9899
Email: rhousa.beaver@wt-group.com

Let’s not pollute our ocean of air

Like we polluted theirs.

AMERICAN LUNG ASSOCIATION

The Christmas Seal People®

Space contributed by the publisher as a public service

Moving?
Look to Classified Notices for practices available in your area.

Help Fight Leukemia
Donate Blood and Platelets

For information on donating blood,
Call 1-800-GIVE-LIFE
Or contact your local Red Cross
Employer-Based Health Insurance Has Wide Support

BY MARY ELLEN SCHNEIDER
Elverson Global Medical News

Most Americans favor a continuation of the employer-based health insurance system and say that they believe health insurance costs should be shared among individuals, employers, and the government, according to the results of a survey conducted by the Commonwealth Fund.

More than two-thirds of Americans who took part would favor a mandate for individuals to obtain health insurance in an effort to provide universal health coverage. These findings indicate that on certain health reform issues Americans’ views may be more closely aligned with the proposals put forth by Democratic candidates for president than those outlined by Republicans.

For example, the leading Democratic candidates for president would require employers to offer health coverage to employees or pay for part of their coverage, while most of the Republican candidates proposed changes to the tax code that could potentially reduce the role of employers in the health insurance market, according to a Commonwealth Fund analysis.

Sen. Hillary Clinton (D-N.Y.) would support an individual health insurance mandate, while Sen. Barack Obama (D-Ill.) would mandate coverage for all children. Of the all Republican candidates, no one proposed an individual insurance mandate, according to the Commonwealth Fund.

In the period from June to October 2007, the Commonwealth Fund conducted a telephone survey of 3,301 adults aged 19 years and older as part of its biennial health insurance survey. The group released the results from four health reform surveys before it announced the other findings, which are scheduled to be released in March.

The survey respondents expressed broad support for an employer-based system of health insurance coverage. About 81% of respondents said that employers should either provide health insurance or contribute to a fund in order to cover all Americans.

Support for an employer-based health insurance system was high among respondents regardless of political affiliation, race, gender, age, and income.

The support for an individual insurance mandate to ensure coverage for all was lower: 68% of the respondents said that they strongly or somewhat favor a requirement that all individuals obtain health insurance. About 25% of the respondents said they strongly or somewhat opposed the idea. About 7% said they did not know, or refused to answer.

When respondents were asked who should pay for health insurance for all Americans, 66% favored a system in which costs would be shared by individuals, employers, and the government. About 15% of respondents said it should be mostly government-financed. 8% said it should be paid for mostly by employers, and 6% favored a system in which individuals pick up the tab. Another 5% of the respondents said they didn’t know, or refused to answer.

The survey also indicated that the candidates’ views on health care reform will be important in determining votes. About 86% of the respondents said that health care reform is very or somewhat important in determining their vote during the presidential election.

Dr. Philip Marcus, FCPP, comments: Health insurance continues to be a major discussion point, and the interest increases during a national election. We continue to debate whether health care is a privilege or a right. Should we just expand the Medicare program to all Americans, including children, so that no one lacks insurance?

Should this be financed by an addition to the already existing Medicare tax deduction, with a portion paid by the employer and another by the employee? We are faced with major decisions concerning how we fund our health care. Each candidate has views to solve the problem, but may or may not be able to “fix” the problem at this time.

BRIEF SUMMARY OF PRESCRIBING INFORMATION

CSL Behring Zemaira®

Alpha-1-Proteinase Inhibitor (Human)

Manufactured by:
CSL Behring LLC
Kankakee, IL 60901 USA

US License No. 1707

Indications and Usage

Zemaira® is indicated for chronic augmentation and maintenance therapy in individuals with alpha-1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema. Zemaira® increases antigen and functional (A1C) serum levels and long-term lapping levels of A1C-P. Clinical trials have demonstrated the improvement of long-term therapy of individuals with Zemaira® are not available.

Safety and effectiveness in pediatric patients have not been established.

Zemaira® is not indicated for therapy in lung disease patients in whom severe congenital A1-PI deficiency has not been established.

Contraindications

Zemaira® is contraindicated in individuals with a known hypersensitivity to any of its components.

Zemaira® is also contraindicated in individuals with a history of anaphylaxis in severe systemic response to A1-PI products.

Individually with selected Ibg deficiencies who have known antibodies against Ibg (anti-Ibg antibodies) should not receive Zemaira® since these patients may experience severe reactions, including anaphylaxis, to Ibg that may be present in Zemaira®.

Warnings

Zemaira® is a recycle from human plasma. Products made from human plasma may contain infectious agents, such as viruses, which can cause disease. Because Zemaira® is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and thereby the transmitted various (AIDS) agent.

The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current or past infections, and by marketing and removing others from plasma by using production (Compares Collection of a large pool of A1-PI products. Individually with selected Ibg deficiencies who have known antibodies against Ibg (anti-Ibg antibodies) should not receive Zemaira® since these patients may experience severe reactions, including anaphylaxis, to Ibg that may be present in Zemaira®.

Breach of Contract

Zemaira® is no claims from human plasma. Products made from human plasma may contain infectious agents, such as viruses which can cause disease. Because Zemaira® is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and thereby the transmitted various (AIDS) agent.

The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current or past infections, and by marketing and removing others from plasma by using production (Compares Collection of a large pool of A1-PI products. Individually with selected Ibg deficiencies who have known antibodies against Ibg (anti-Ibg antibodies) should not receive Zemaira® since these patients may experience severe reactions, including anaphylaxis, to Ibg that may be present in Zemaira®.

Dosing Information

Zemaira® is indicated for chronic augmentation and maintenance therapy in individuals with alpha-1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema. Zemaira® increases antigen and functional (A1C) serum levels and long-term lapping levels of A1C-P. Clinical trials have demonstrated the improvement of long-term therapy of individuals with Zemaira® are not available.

Safety and effectiveness in pediatric patients have not been established.

Zemaira® is not indicated for therapy in lung disease patients in whom severe congenital A1-PI deficiency has not been established.

Contraindications

Zemaira® is contraindicated in individuals with a known hypersensitivity to any of its components.

Zemaira® is also contraindicated in individuals with a history of anaphylaxis in severe systemic response to A1-PI products.

Individually with selected Ibg deficiencies who have known antibodies against Ibg (anti-Ibg antibodies) should not receive Zemaira® since these patients may experience severe reactions, including anaphylaxis, to Ibg that may be present in Zemaira®.

Breach of Contract

Zemaira® is no claims from human plasma. Products made from human plasma may contain infectious agents, such as viruses which can cause disease. Because Zemaira® is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and thereby the transmitted various (AIDS) agent.

The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current or past infections, and by marketing and removing others from plasma by using production (Compares Collection of a large pool of A1-PI products. Individually with selected Ibg deficiencies who have known antibodies against Ibg (anti-Ibg antibodies) should not receive Zemaira® since these patients may experience severe reactions, including anaphylaxis, to Ibg that may be present in Zemaira®.

Dosing Information

Zemaira® is indicated for chronic augmentation and maintenance therapy in individuals with alpha-1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema. Zemaira® increases antigen and functional (A1C) serum levels and long-term lapping levels of A1C-P. Clinical trials have demonstrated the improvement of long-term therapy of individuals with Zemaira® are not available.

Safety and effectiveness in pediatric patients have not been established.

Zemaira® is not indicated for therapy in lung disease patients in whom severe congenital A1-PI deficiency has not been established.

Contraindications

Zemaira® is contraindicated in individuals with a known hypersensitivity to any of its components.

Zemaira® is also contraindicated in individuals with a history of anaphylaxis in severe systemic response to A1-PI products.

Individually with selected Ibg deficiencies who have known antibodies against Ibg (anti-Ibg antibodies) should not receive Zemaira® since these patients may experience severe reactions, including anaphylaxis, to Ibg that may be present in Zemaira®.
Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira® are not available. As with other Alpha-1 therapies, Zemaira® may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse events were reported in 1% of subjects: asthenia, injection-site pain, dizziness, headache, paresthesia, and pruritus.

Zemaira® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

For more information, call 1-866-ZEMAIRA (1-866-936-2472), or visit www.Zemaira.com.

References: 1. Prolastin® Alpha-Proteinase Inhibitor (Human), Full Prescribing Information, January 2005. 2. Aralast® Alpha-Proteinase Inhibitor (Human), Full Prescribing Information, August 2005. 3. Data on file, CSL Behring LLC.

Please see brief summary of full prescribing information on following page.
* Shelf life purity specification is ≥90%.
† In a retrospective analysis in the pivotal clinical trial, Zemaira® patients were three times less likely to experience exacerbations of their COPD than Prolastin® patients.
‡ No clinically significant differences were detected between the treatment groups.
§ Based on recommended dosage as stated in the product package inserts of 60 mg/kg body weight at the infusion rate of 0.08 mL/kg/min.

Prolastin is a registered trademark of Talecris Biotherapeutics, Inc.

---

**For adults with Alpha-1 antitrypsin deficiency**

Zemaira® — The next generation in purity for Alpha-1 augmentation therapy

- **Pure** — The only Alpha-1 augmentation therapy approved by the FDA as highly purified (lot release specification, ≥94% purity)*,1-3
- **Effective** — Three times fewer COPD exacerbations than with Prolastin®†
- **Well tolerated** — Six times fewer infusion-related adverse events than with Prolastin®‡
- **Fast** — Half or less the infusion time of other augmentation therapies1,3